ClinicalTrials.gg
CompletedNCT00328627Updated Apr 4, 2013Results posted

Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.

A Phase 3 interventional study of Alogliptin and Alogliptin placebo in Type 2 Diabetes Mellitus, sponsored by Takeda. Completed at 90 sites in 19 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2013-04-04.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,554
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 39 studies testing alogliptin in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. alogliptin · Diabetes Mellitus, Type 2.

Enrollment
4th of 39
1,554 · median 329
Started
2006
with 7 others
Phase 3
16 of 39
none open now
Registered
7th of 39
by date
Lead sponsor
30 of 39
Takeda

Among the 39 studies testing alogliptin in Diabetes Mellitus, Type 2, this one is the 4th largest by enrollment, is one of 8 that started in 2006, is one of 16 in phase 3, and was the 7th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 39 studies testing alogliptin in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About alogliptin

alogliptin: first FDA approval 2013 (NESINA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 39 studies testing alogliptin in Diabetes Mellitus, Type 2 as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of alogliptin, once daily (QD), taken in combination with pioglitazone in adults with type 2 diabetes mellitus.

Read the detailed description

Over the past 30 years, the prevalence of diabetes has increased dramatically throughout the world due to population growth, aging, urbanization, increasing obesity, and physical inactivity. The total number of people with type 2 diabetes mellitus is projected to rise from 171 million in 2000 to 366 million in 2030. The incidence of type 2 diabetes mellitus in the United States alone is expected to increase from approximately 17 to 30.3 million by the year 2030. Type 2 diabetes mellitus is associated with a number of long-term microvascular and macrovascular complications associated with a reduced quality of life and increased morbidity and mortality. It is anticipated that the increasing incidence of type 2 diabetes mellitus will place an ever-increasing burden on families, increase national expenditures for health care services, and decrease worker productivity.

Current pharmacologic interventions for type 2 diabetes mellitus include a diverse range of antidiabetic medications with different mechanisms of action including insulin and insulin analogues, sulfonylureas, metformin, meglitinides, thiazolidinediones, inhibitors of alpha-glucosidase, analogs of glucagon-like peptide-1 and synthetic analogues of human amylin. Despite the variety of medications, many have clinically important or potentially life-threatening side effects, restricted use in many subpopulations, concerns with long-term tolerability, and challenges related to compliance due to side effects and route of administration. All of these reasons contribute to the difficulties patients have achieving the target glycosylated hemoglobin level less than 7%.

SYR-322 (alogliptin) is a selective, orally available inhibitor of the dipeptidyl peptidase-4 enzyme. Dipeptidyl peptidase-4 enzyme is thought to be primarily responsible for the in vivo degradation of 2 peptide hormones released in response to nutrient ingestion, namely glucagon-like peptide-1 and glucose-dependent insulinotropic peptide. Both peptides exert important effects on islet beta cells to stimulate glucose-dependent insulin secretion as well as regulating beta cell proliferation and cytoprotection. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits gastric emptying, glucagon secretion, and food intake. Glucose-dependent insulinotropic peptide has been shown to enhance insulin secretion by direct interaction with a glucose-dependent insulinotropic peptide -specific receptor on islet beta cells. The glucose-lowering actions of glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, are preserved in patients with type 2 diabetes mellitus.

Pioglitazone (ACTOS®) is a thiazolidinedione developed by Takeda Chemical Industries, Ltd. (Osaka, Japan) that is approved for the treatment of type 2 diabetes mellitus. Pioglitazone is a selective peroxisome proliferator-activated receptor-gamma agonist that decreases insulin resistance in the periphery and liver resulting in increased insulin-dependent glucose disposal and decreased hepatic glucose output.

Given the complementary mechanisms of action of alogliptin (stimulation of insulin secretion) and pioglitazone (enhancement of insulin sensitivity), the goal of this study is to evaluate the efficacy of the combination of alogliptin with pioglitazone in patients who are inadequately controlled on metformin. Study participation is anticipated to be approximately 7 months.

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • Diabetes Mellitus, Type 2
  • Drug Therapy
  • Diabetes Mellitus, Non Insulin Dependent
  • Glucose Intolerance
  • Hyperglycemia
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women with a historical diagnosis of type 2 diabetes mellitus who were treated with metformin greater than or equal to 1500 mg alone but were experiencing inadequate glycemic control.
  • A stable dose of metformin of greater than or equal to 1500 mg or maximum tolerated dose.
  • No treatment with antidiabetic agents other than metformin within the 2 months prior to Screening.
  • A greater than or equal to 23 kg/m\^2 and less than or equal to 45 kg/m\^2.
  • Fasting C-peptide greater than or equal to 0.8 ng/mL.
  • Regular use of other, non-excluded medications was allowed if a stable dose had been established for at least 4 weeks prior to Screening.
  • Systolic blood pressure less than or equal to 160 mmHg and diastolic pressure less than or equal to 100 mmHg.
  • greater than or equal to 12 g/dL for men and greater than or equal to 10 g/dL for women.
  • less than or equal to 2.5 times the .
  • Serum creatinine less than 1.5 mg/dL for men and less than 1.4 mg/dL for women.
  • Thyroid-stimulating hormone level less than or equal to the upper limit of the normal range and the subject was clinically euthyroid.
  • Females of who are sexually active must agree to use adequate , and can neither be pregnant nor lactating from Screening throughout the duration of the study.
  • Able and willing to monitor their own blood glucose concentrations with a home glucose monitor.
  • No major illness or debility that in the investigator's opinion prohibited the patient from completing the study.

Exclusion criteria

Exclusion Criteria:

  • Urine albumin/creatinine ratio greater than 113 mg/mmol at Screening.
  • A history of cancer, other than squamous cell or basal cell carcinoma of the skin, that had not been in full remission for at least 5 years prior to Screening.
  • A history of laser treatment for proliferative diabetic retinopathy within 6 months prior to Screening.
  • A history of treated diabetic gastroparesis.
  • Class III or IV heart failure regardless of therapy.
  • History of coronary angioplasty, coronary stent placement, coronary bypass surgery, or myocardial infarction within the 6 months prior to Screening.
  • History of any hemoglobinopathy.
  • History of infection with , or .
  • History of a psychiatric disorder that could have affected the patient's ability to participate in the study.
  • History of angioedema in association with use of angiotensin-converting enzyme inhibitors or angiotensin-II receptor inhibitors.
  • A history of alcohol or substance abuse within 2 years prior to Screening.
  • Receipt of any drug within 30 days prior to Screening or a history of receipt of an investigational antidiabetic drug within 3 months prior to Screening.
  • Previous participation in an investigational study of alogliptin.
  • Hypersensitive to pioglitazone, alogliptin, or other .
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,554 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.

    Drug: Alogliptin placebo · Drug: Pioglitazone placebo

  • Experimental
    Alogliptin 12.5 + Placebo

    Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.

    Drug: Alogliptin · Drug: Pioglitazone placebo

  • Experimental
    Alogliptin 25 + Placebo

    Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.

    Drug: Alogliptin · Drug: Pioglitazone placebo

  • Active comparator
    Placebo + Pioglitazone 15

    Alogliptin placebo-matching tablets, orally, once daily and pioglitazone 15 mg, tablets, orally, once daily for up to 26 weeks.

    Drug: Pioglitazone

  • Experimental
    Alogliptin 12.5 + Pioglitazone 15

    Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 15 mg, tablets, orally, once daily for up to 26 weeks.

    Drug: Alogliptin · Drug: Pioglitazone

  • Experimental
    Alogliptin 25 + Pioglitazone 15

    Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 15 mg, tablets, orally, once daily for up to 26 weeks.

    Drug: Alogliptin · Drug: Pioglitazone

  • Active comparator
    Placebo + Pioglitazone 30

    Alogliptin placebo-matching tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.

    Drug: Alogliptin placebo · Drug: Pioglitazone

  • Experimental
    Alogliptin 12.5 + Pioglitazone 30

    Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.

    Drug: Alogliptin · Drug: Pioglitazone

  • Experimental
    Alogliptin 25 + Pioglitazone 30

    Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.

    Drug: Alogliptin · Drug: Pioglitazone

  • Active comparator
    Placebo + Pioglitazone 45

    Alogliptin placebo-matching tablets, orally, once daily and pioglitazone 45 mg, tablets, orally, once daily for up to 26 weeks.

    Drug: Alogliptin placebo · Drug: Pioglitazone

  • Experimental
    Alogliptin 12.5 + Pioglitazone 45

    Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 45 mg, tablets, orally, once daily for up to 26 weeks.

    Drug: Alogliptin · Drug: Pioglitazone

  • Experimental
    Alogliptin 25 + Pioglitazone 45

    Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 45 mg, tablets, orally, once daily for up to 26 weeks.

    Drug: Alogliptin · Drug: Pioglitazone

Interventions

  • Alogliptin tablets.

    Also known as: SYR-322

  • DrugAlogliptin placebo

    Alogliptin placebo-matching tablets.

  • Pioglitazone tablets.

    Also known as: ACTOS®

  • DrugPioglitazone placebo

    Pioglitazone placebo-matching tablets.

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 26 in Glycosylated Hemoglobin (HbA1c) (Grouped Analysis)

    The change from Baseline to Week 26 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound). The primary analysis compared the groupings (combinations of individual treatment groups) of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone (Pioglitazone Alone).

    Time frame: Baseline and Week 26

  2. Change From Baseline to Week 26 in HbA1c

    The change from Baseline to Week 26 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound).

    Time frame: Baseline and Week 26

Secondary outcomes

  1. Change From Baseline in HbA1c Over Time (Grouped Analysis)

    The change from Baseline to Weeks 4, 8, 12, 16 and 20 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound). This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an analysis of covariance (ANCOVA) model with treatment and geographic region as class variables, and baseline metformin dose and HbA1c as continuous covariates.

    Time frame: Baseline and Weeks 4, 8, 12, 16 and 20.

  2. Change From Baseline to Week 4 in HbA1c

    The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at week 4. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HbA1c as continuous covariates.

    Time frame: Baseline and Week 4

  3. Change From Baseline to Week 8 in HbA1c

    The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at week 8. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HbA1c as continuous covariates.

    Time frame: Baseline and Week 8

  4. Change From Baseline to Week 12 in HbA1c

    The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at week 12. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HbA1c as continuous covariates.

    Time frame: Baseline and Week 12

  5. Change From Baseline to Week 16 in HbA1c

    The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at week 16. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HbA1c as continuous covariates.

    Time frame: Baseline and Week 16

  6. Change From Baseline to Week 20 in HbA1c

    The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at week 20. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HbA1c as continuous covariates.

    Time frame: Baseline and Week 20

  7. Change From Baseline in Fasting Plasma Glucose Over Time (Grouped Analysis)

    The change from Baseline in fasting plasma glucose was assessed at weeks 1, 2, 4, 8, 12, 16, 20 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline fasting plasma glucose as covariates.

    Time frame: Baseline and Weeks 1, 2, 4, 8, 12, 16, 20 and 26.

  8. Change From Baseline to Week 1 in Fasting Plasma Glucose

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline fasting plasma glucose as covariates.

    Time frame: Baseline and Week 1

  9. Change From Baseline to Week 2 in Fasting Plasma Glucose

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline fasting plasma glucose as covariates.

    Time frame: Baseline and Week 2

  10. Change From Baseline to Week 4 in Fasting Plasma Glucose

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline fasting plasma glucose as covariates.

    Time frame: Baseline and Week 4

  11. Change From Baseline to Week 8 in Fasting Plasma Glucose

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline fasting plasma glucose as covariates.

    Time frame: Baseline and Week 8

  12. Change From Baseline to Week 12 in Fasting Plasma Glucose

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline fasting plasma glucose as covariates.

    Time frame: Baseline and Week 12

  13. Change From Baseline to Week 16 in Fasting Plasma Glucose

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline fasting plasma glucose as covariates.

    Time frame: Baseline and Week 16

  14. Change From Baseline to Week 20 in Fasting Plasma Glucose

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline fasting plasma glucose as covariates.

    Time frame: Baseline and Week 20

  15. Change From Baseline to Week 26 in Fasting Plasma Glucose

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline fasting plasma glucose as covariates.

    Time frame: Baseline and Week 26

  16. Percentage of Participants With Marked Hyperglycemia (Grouped Analysis)

    Marked hyperglycemia is defined as fasting plasma glucose greater than or equal to 200 mg/dL (11.10 mmol/L). This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone.

    Time frame: From Week 1 to Week 26

  17. Percentage of Participants With Marked Hyperglycemia

    Marked hyperglycemia is defined as fasting plasma glucose greater than or equal to 200 mg/dL (11.10 mmol/L).

    Time frame: From Week 1 to Week 26

  18. Percentage of Participants Meeting Rescue Criteria (Grouped Analysis)

    Rescue was defined as meeting 1 of the following criteria, confirmed by a 2nd sample drawn within 5 days of the first and analyzed by the central laboratory: 1. After the Week 1 Visit but prior to the Week 4 Visit: a single fasting plasma glucose ≥300 mg/dL; 2. From the Week 4 Visit but prior to the Week 8 Visit: a single fasting plasma glucose ≥275 mg/dL; 3. From the Week 8 Visit but prior to the Week 12 Visit: a single fasting plasma glucose ≥250 mg/dL; 4. From the Week 12 Visit through the End-of-Treatment Visit: HbA1c ≥8.5% and ≤0.5% reduction in HbA1c as compared with Baseline HbA1c.

    Time frame: From Week 1 to Week 26.

  19. Percentage of Participants Meeting Rescue Criteria

    Rescue was defined as meeting 1 of the following criteria, confirmed by a 2nd sample drawn within 5 days of the first and analyzed by the central laboratory: 1. After the Week 1 Visit but prior to the Week 4 Visit: a single fasting plasma glucose ≥300 mg/dL; 2. From the Week 4 Visit but prior to the Week 8 Visit: a single fasting plasma glucose ≥275 mg/dL; 3. From the Week 8 Visit but prior to the Week 12 Visit: a single fasting plasma glucose ≥250 mg/dL; 4. From the Week 12 Visit through the End-of-Treatment Visit: HbA1c ≥8.5% and ≤0.5% reduction in HbA1c as compared with Baseline HbA1c.

    Time frame: From Week 1 to Week 26

  20. Percentage of Participants With Glycosylated Hemoglobin ≤ 6.5% (Grouped Analysis)

    Clinical response at Week 26 was assessed by the percentage of participants with HbA1c less than or equal to 6.5%. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone.

    Time frame: Week 26

  21. Percentage of Participants With Glycosylated Hemoglobin ≤ 6.5%

    Clinical response at Week 26 was assessed by the percentage of participants with HbA1c less than or equal to 6.5%.

    Time frame: Week 26

  22. Percentage of Participants With Glycosylated Hemoglobin ≤ 7.0% (Grouped Analysis)

    Clinical response at Week 26 was assessed by the percentage of participants with HbA1c less than or equal to 7%. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone.

    Time frame: Week 26

  23. Percentage of Participants With Glycosylated Hemoglobin ≤ 7%

    Clinical response at Week 26 was assessed by the percentage of participants with HbA1c less than or equal to 7%.

    Time frame: Week 26

  24. Percentage of Participants With Glycosylated Hemoglobin ≤ 7.5% (Grouped Analysis)

    Clinical response at Week 26 was assessed by the percentage of participants with HbA1c less than or equal to 7.5%. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone.

    Time frame: Week 26

  25. Percentage of Participants With Glycosylated Hemoglobin ≤ 7.5%

    Clinical response at Week 26 was assessed by the percentage of participants with HbA1c less than or equal to 7.5%.

    Time frame: Week 26

  26. Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 0.5% (Grouped Analysis)

    Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 0.5%. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone.

    Time frame: Baseline and Week 26

  27. Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 0.5%

    Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 0.5%.

    Time frame: Baseline and Week 26

  28. Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 1% (Grouped Analysis)

    Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 1%. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone.

    Time frame: Baseline and Week 26

  29. Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 1%

    Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 1%.

    Time frame: Baseline and Week 26

  30. Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 1.5% (Grouped Analysis)

    Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 1.5%. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone.

    Time frame: Baseline and Week 26

  31. Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 1.5%

    Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 1.5%.

    Time frame: Baseline and Week 26

  32. Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 2.0% (Grouped Analysis)

    Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 2.0%. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone.

    Time frame: Baseline and Week 26.

  33. Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 2%

    Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 2%.

    Time frame: Baseline and Week 26

  34. Change From Baseline in Fasting Proinsulin Over Time (Grouped Analysis)

    Proinsulin is a precursor to insulin, and was measured as an indicator of pancreatic function. The change from Baseline in fasting proinsulin was assessed at Weeks 4, 8, 12, 16, 20 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and proinsulin as continuous covariates.

    Time frame: Baseline and Weeks 4, 8, 12, 16, 20 and 26.

  35. Change From Baseline to Week 4 in Fasting Proinsulin

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin as continuous covariates.

    Time frame: Baseline and Week 4

  36. Change From Baseline to Week 8 in Fasting Proinsulin

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin as continuous covariates.

    Time frame: Baseline and Week 8

  37. Change From Baseline to Week 12 in Fasting Proinsulin

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin as continuous covariates.

    Time frame: Baseline and Week 12

  38. Change From Baseline to Week 16 in Fasting Proinsulin

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin as continuous covariates.

    Time frame: Baseline and Week 16

  39. Change From Baseline to Week 20 in Fasting Proinsulin

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin as continuous covariates.

    Time frame: Baseline and Week 20

  40. Change From Baseline to Week 26 in Fasting Proinsulin

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin as continuous covariates.

    Time frame: Baseline and Week 26

  41. Change From Baseline in Insulin Over Time (Grouped Analysis)

    The change from Baseline in fasting insulin was assessed at Weeks 4, 8, 12, 16, 20 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline insulin as continuous covariates.

    Time frame: Baseline and Weeks 4, 8, 12, 16, 20 and 26.

  42. Change From Baseline to Week 4 in Insulin Levels

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline insulin as continuous covariates.

    Time frame: Baseline and Week 4

  43. Change From Baseline to Week 8 in Insulin Levels

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline insulin as continuous covariates.

    Time frame: Baseline and Week 8

  44. Change From Baseline to Week 12 in Insulin Levels

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline insulin as continuous covariates.

    Time frame: Baseline and Week 12

  45. Change From Baseline to Week 16 in Insulin Levels

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline insulin as continuous covariates.

    Time frame: Baseline and Week 16

  46. Change From Baseline to Week 20 in Insulin Levels

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline insulin as continuous covariates.

    Time frame: Baseline and Week 20

  47. Change From Baseline to Week 26 in Insulin Levels

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline insulin as continuous covariates.

    Time frame: Baseline and Week 26

  48. Change From Baseline in Proinsulin/Insulin Ratio Over Time (Grouped Analysis)

    The ratio of proinsulin to insulin was calculated as proinsulin (pmol/L) / insulin (μIU/mL) at weeks 4, 8, 12, 16, 20 and 26 relative to the Baseline value. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin/insulin ratio as continuous covariates.

    Time frame: Baseline and Weeks 4, 8, 12, 16, 20 and 26.

  49. Change From Baseline to Week 4 in Proinsulin/Insulin Ratio

    The ratio of proinsulin to insulin was calculated as proinsulin (pmol/L) / insulin (μIU/mL). Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin/insulin ratio as continuous covariates.

    Time frame: Baseline and Week 4

  50. Change From Baseline to Week 8 in Proinsulin/Insulin Ratio

    The ratio of proinsulin to insulin was calculated as proinsulin (pmol/L) / insulin (μIU/mL). Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin/insulin ratio as continuous covariates.

    Time frame: Baseline and Week 8

  51. Change From Baseline to Week 12 in Proinsulin/Insulin Ratio

    The ratio of proinsulin to insulin was calculated as proinsulin (pmol/L) / insulin (μIU/mL). Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin/insulin ratio as continuous covariates.

    Time frame: Baseline and Week 12

  52. Change From Baseline to Week 16 in Proinsulin/Insulin Ratio

    The ratio of proinsulin to insulin was calculated as proinsulin (pmol/L) / insulin (μIU/mL). Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin/insulin ratio as continuous covariates.

    Time frame: Baseline and Week 16

  53. Change From Baseline to Week 20 in Proinsulin/Insulin Ratio

    The ratio of proinsulin to insulin was calculated as proinsulin (pmol/L) / insulin (μIU/mL). Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin/insulin ratio as continuous covariates.

    Time frame: Baseline and Week 20

  54. Change From Baseline to Week 26 in Proinsulin/Insulin Ratio

    The ratio of proinsulin to insulin was calculated as proinsulin (pmol/L) / insulin (μIU/mL). Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin/insulin ratio as continuous covariates.

    Time frame: Baseline and Week 26

  55. Change From Baseline in C-peptide Over Time (Grouped Analysis)

    C-peptide is a byproduct created when the hormone insulin is produced and is measured by a blood test. Change from Baseline was assessed at Weeks 4, 8, 12, 16, 20 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline C-peptide as continuous covariates.

    Time frame: Baseline and Weeks 4, 8, 12, 16, 20 and 26.

  56. Change From Baseline to Week 4 in C-peptide Levels

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline C-peptide as continuous covariates.

    Time frame: Baseline and Week 4

  57. Change From Baseline to Week 8 in C-peptide Levels

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline C-peptide as continuous covariates.

    Time frame: Baseline and Week 8

  58. Change From Baseline to Week 12 in C-peptide Levels

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline C-peptide as continuous covariates.

    Time frame: Baseline and Week 12

  59. Change From Baseline to Week 16 in C-peptide Levels

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline C-peptide as continuous covariates.

    Time frame: Baseline and Week 16

  60. Change From Baseline to Week 20 in C-peptide Levels

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline C-peptide as continuous covariates.

    Time frame: Baseline and Week 20

  61. Change From Baseline to Week 26 in C-peptide Levels

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline C-peptide as continuous covariates.

    Time frame: Baseline and Week 26

  62. Change From Baseline in Total Cholesterol Over Time (Grouped Analysis)

    Change from Baseline in total cholesterol was assessed at Weeks 4, 8, 12, 16, 20 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline total cholesterol as continuous covariates.

    Time frame: Baseline and Weeks 4, 8, 12, 16, 20 and 26.

  63. Change From Baseline to Week 4 in Total Cholesterol Levels

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline total cholesterol as continuous covariates.

    Time frame: Baseline and Week 4

  64. Change From Baseline to Week 8 in Total Cholesterol Levels

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline total cholesterol as continuous covariates.

    Time frame: Baseline and Week 8

  65. Change From Baseline to Week 12 in Total Cholesterol Levels

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline total cholesterol as continuous covariates.

    Time frame: Baseline and Week 12

  66. Change From Baseline to Week 16 in Total Cholesterol Levels

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline total cholesterol as continuous covariates.

    Time frame: Baseline and Week 16

  67. Change From Baseline to Week 20 in Total Cholesterol Levels

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline total cholesterol as continuous covariates.

    Time frame: Baseline and Week 20

  68. Change From Baseline to Week 26 in Total Cholesterol Levels

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline total cholesterol as continuous covariates.

    Time frame: Baseline and Week 26

  69. Change From Baseline in Low-Density Lipoprotein Cholesterol Over Time (Grouped Analysis)

    Change from Baseline in low-density lipoprotein cholesterol (LDL-C) was assessed at Weeks 4, 8, 12, 16, 20 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline LDL cholesterol as continuous covariates.

    Time frame: Baseline and Weeks 4, 8, 12, 16, 20 and 26.

  70. Change From Baseline to Week 4 in Low-Density Lipoprotein Cholesterol

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline LDL cholesterol as continuous covariates.

    Time frame: Baseline and Week 4

  71. Change From Baseline to Week 8 in Low-Density Lipoprotein Cholesterol

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline LDL cholesterol as continuous covariates.

    Time frame: Baseline and Week 8

  72. Change From Baseline to Week 12 in Low-Density Lipoprotein Cholesterol

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline LDL cholesterol as continuous covariates.

    Time frame: Baseline and Week 12

  73. Change From Baseline to Week 16 in Low-Density Lipoprotein Cholesterol

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline LDL cholesterol as continuous covariates.

    Time frame: Baseline and Week 16

  74. Change From Baseline to Week 20 in Low-Density Lipoprotein Cholesterol

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline LDL cholesterol as continuous covariates.

    Time frame: Baseline and Week 20

  75. Change From Baseline to Week 26 in Low-Density Lipoprotein Cholesterol

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline LDL cholesterol as continuous covariates.

    Time frame: Baseline and Week 26

  76. Change From Baseline in High-Density Lipoprotein Cholesterol Over Time (Grouped Analysis)

    Change from Baseline in high-density lipoprotein cholesterol (HDL-C) was assessed at Weeks 4, 8, 12, 16, 20 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HDL cholesterol as continuous covariates.

    Time frame: Baseline and Weeks 4, 8, 12, 16, 20 and 26.

  77. Change From Baseline to Week 4 in High-Density Lipoprotein Cholesterol

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HDL cholesterol as continuous covariates.

    Time frame: Baseline and Week 4

  78. Change From Baseline to Week 8 in High-Density Lipoprotein Cholesterol

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HDL cholesterol as continuous covariates.

    Time frame: Baseline and Week 8

  79. Change From Baseline to Week 12 in High-Density Lipoprotein Cholesterol

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HDL cholesterol as continuous covariates.

    Time frame: Baseline and Week 12

  80. Change From Baseline to Week 16 in High-Density Lipoprotein Cholesterol

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HDL cholesterol as continuous covariates.

    Time frame: Baseline and Week 16

  81. Change From Baseline to Week 20 in High-Density Lipoprotein Cholesterol

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HDL cholesterol as continuous covariates.

    Time frame: Baseline and Week 20

  82. Change From Baseline to Week 26 in High-Density Lipoprotein Cholesterol

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HDL cholesterol as continuous covariates.

    Time frame: Baseline and Week 26

  83. Change From Baseline in Triglycerides Over Time (Grouped Analysis)

    Change from Baseline in triglycerides was assessed at Weeks 4, 8, 12, 16, 20 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline triglycerides as continuous covariates.

    Time frame: Baseline and Weeks 4, 8, 12, 16, 20 and 26.

  84. Change From Baseline to Week 4 in Triglyceride Levels

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline triglycerides as continuous covariates.

    Time frame: Baseline and Week 4

  85. Change From Baseline to Week 8 in Triglyceride Levels

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline triglycerides as continuous covariates.

    Time frame: Baseline and Week 8

  86. Change From Baseline to Week 12 in Triglyceride Levels

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline triglycerides as continuous covariates.

    Time frame: Baseline and Week 12

  87. Change From Baseline to Week 16 in Triglyceride Levels

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline triglycerides as continuous covariates.

    Time frame: Baseline and Week 16

  88. Change From Baseline to Week 20 in Triglyceride Levels

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline triglycerides as continuous covariates.

    Time frame: Baseline and Week 20

  89. Change From Baseline to Week 26 in Triglyceride Levels

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline triglycerides as continuous covariates.

    Time frame: Baseline and Week 26

  90. Change From Baseline in Free Fatty Acids Over Time (Grouped Analysis)

    Change from Baseline in free fatty acids (FFA) was assessed at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline free fatty acid as continuous covariates.

    Time frame: Baseline and Weeks 12 and 26.

  91. Change From Baseline to Week 12 in Free Fatty Acids

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline free fatty acid as continuous covariates.

    Time frame: Baseline and Week 12

  92. Change From Baseline to Week 26 in Free Fatty Acids

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline free fatty acid as continuous covariates.

    Time frame: Baseline and Week 26

  93. Change From Baseline in Plasminogen Activator Inhibitor-1 Over Time (Grouped Analysis)

    Change from Baseline in plasminogen activator inhibitor-1 (PAI-1) was assessed at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline PAI-1 as continuous covariates.

    Time frame: Baseline and Weeks 12 and 26.

  94. Change From Baseline to Week 12 in Plasminogen Activator Inhibitor-1

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline PAI-1 as continuous covariates.

    Time frame: Baseline and Week 12

  95. Change From Baseline to Week 26 in Plasminogen Activator Inhibitor-1

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline PAI-1 as continuous covariates.

    Time frame: Baseline and Week 26

  96. Change From Baseline in High-sensitivity C-Reactive Protein Over Time (Grouped Analysis)

    Change from Baseline in high-sensitivity C-Reactive Protein (hsCRP) was assessed at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline hsCRP as continuous covariates.

    Time frame: Baseline and Weeks 12 and 26.

  97. Change From Baseline to Week 12 in High-sensitivity C-Reactive Protein

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline hsCRP as continuous covariates.

    Time frame: Baseline and Week 12

  98. Change From Baseline to Week 26 in High-sensitivity C-Reactive Protein

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline hsCRP as continuous covariates.

    Time frame: Baseline and Week 26

  99. Change From Baseline in Adiponectin Over Time (Grouped Analysis)

    Change from Baseline in adiponectin was assessed at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline adiponectin as continuous covariates.

    Time frame: Baseline and Weeks 12 and 26.

  100. Change From Baseline to Week 12 in Adiponectin

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline adiponectin as continuous covariates.

    Time frame: Baseline and Week 12

  101. Change From Baseline to Week 26 in Adiponectin

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline adiponectin as continuous covariates.

    Time frame: Baseline and Week 26

  102. Change From Baseline in Body Weight Over Time (Grouped Analysis)

    Change from Baseline in body weight was assessed at Weeks 8, 12, 20 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline weight as continuous covariates.

    Time frame: Baseline and Weeks 8, 12, 20 and 26.

  103. Change From Baseline to Week 8 in Body Weight

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline weight as continuous covariates.

    Time frame: Baseline and Week 8

  104. Change From Baseline to Week 12 in Body Weight

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline weight as continuous covariates.

    Time frame: Baseline and Week 12

  105. Change From Baseline to Week 20 in Body Weight

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline weight as continuous covariates.

    Time frame: Baseline and Week 20

  106. Change From Baseline to Week 26 in Body Weight

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline weight as continuous covariates.

    Time frame: Baseline and Week 26

  107. Change From Baseline in Calculated Homeostatic Model Assessment Insulin Resistance (HOMA IR) (Grouped Analysis)

    HOMA IR measures insulin resistance based on fasting glucose and insulin measurements: HOMA IR = fasting plasma insulin (µIU/mL) \* fasting plasma glucose (mmol/L) / 22.5. A higher number indicates a greater insulin resistance. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least Squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and HOMA-IR as continuous covariates.

    Time frame: Baseline and Weeks 12 and 26.

  108. Change From Baseline to Week 12 in Calculated HOMA Insulin Resistance

    The Homeostasis Model Assessment of insulin resistance (HOMA IR) measures insulin resistance based on fasting glucose and insulin measurements: HOMA IR = fasting plasma insulin (µIU/mL) \* fasting plasma glucose (mmol/L) / 22.5. A higher number indicates a greater degree of insulin resistance. Least Squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and HOMA-IR as continuous covariates.

    Time frame: Baseline and Week 12

  109. Change From Baseline to Week 26 in Calculated HOMA Insulin Resistance

    The Homeostasis Model Assessment of insulin resistance (HOMA IR) measures insulin resistance based on fasting glucose and insulin measurements: HOMA IR = fasting plasma insulin (µIU/mL) \* fasting plasma glucose (mmol/L) / 22.5. A higher number indicates a greater degree of insulin resistance. Least Squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and HOMA-IR as continuous covariates.

    Time frame: Baseline and Week 26

  110. Change From Baseline in Homeostatic Model Assessment Beta Cell Function (Grouped Analysis)

    The homeostatic model assessment estimates steady state beta cell function as a percentage of a normal reference population (%B). HOMA %B = 20 \* insulin (µIU/mL) / fasting plasma glucose (mmol/L) - 3.5. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HOMA beta cell function as continuous covariates.

    Time frame: Baseline and Weeks 12 and 26

  111. Change From Baseline to Week 12 in Calculated HOMA Beta-cell Function

    The Homeostasis Model Assessment (HOMA) estimates steady state beta cell function (%B) as a percentage of a normal reference population. HOMA %B = 20 \* insulin (µIU/mL) / fasting plasma glucose (mmol/L) - 3.5. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HOMA beta cell function as continuous covariates.

    Time frame: Baseline and Week 12

  112. Change From Baseline to Week 26 in Calculated HOMA Beta-cell Function

    The Homeostasis Model Assessment (HOMA) estimates steady state beta cell function (%B) as a percentage of a normal reference population. HOMA %B = 20 \* insulin (µIU/mL) / fasting plasma glucose (mmol/L) - 3.5. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HOMA beta cell function as continuous covariates.

    Time frame: Baseline and Week 26

  113. Change From Baseline in Apolipoprotein A1 Over Time (Grouped Analysis)

    Change from Baseline in Apolipoprotein A1 was assessed at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein A1 as continuous covariates.

    Time frame: Baseline and Weeks 12 and 26.

  114. Change From Baseline to Week 12 in Apolipoprotein A1

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein A1 as continuous covariates.

    Time frame: Baseline and Week 12

  115. Change From Baseline to Week 26 in Apolipoprotein A1

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein A1 as continuous covariates.

    Time frame: Baseline and Week 26

  116. Change From Baseline in Apolipoprotein A2 Over Time (Grouped Analysis)

    Change from Baseline in Apolipoprotein A2 was assessed at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein A2 as continuous covariates.

    Time frame: Baseline and Weeks 12 and 26

  117. Change From Baseline to Week 12 in Apolipoprotein A2

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein A2 as continuous covariates.

    Time frame: Baseline and Week 12

  118. Change From Baseline to Week 26 in Apolipoprotein A2

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein A2 as continuous covariates.

    Time frame: Baseline and Week 26

  119. Change From Baseline in Apolipoprotein B Over Time (Grouped Analysis)

    Change from Baseline in Apolipoprotein B was assessed at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein B as continuous covariates.

    Time frame: Baseline and Weeks 12 and 26

  120. Change From Baseline to Week 12 in Apolipoprotein B

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein B as continuous covariates.

    Time frame: Baseline and Week 12

  121. Change From Baseline to Week 26 in Apolipoprotein B

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein B as continuous covariates.

    Time frame: Baseline and Week 26

  122. Change From Baseline in Apolipoprotein C-III Over Time (Grouped Analysis)

    Change from Baseline in apolipoprotein C-III was assessed at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein C-III as continuous covariates.

    Time frame: Baseline and Weeks 12 and 26

  123. Change From Baseline to Week 12 in Apolipoprotein C-III

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein C-III as continuous covariates.

    Time frame: Baseline and Week 12

  124. Change From Baseline to Week 26 in Apolipoprotein C-III

    Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein C-III as continuous covariates.

    Time frame: Baseline and Week 26

  125. Change From Baseline in Nuclear Magnetic Resonance Lipid Fractionation Total Triglycerides Over Time (Grouped Analysis)

    Nuclear Magnetic Resonance (NMR) lipid fractionation was used to assess the change from Baseline in total triglyceride levels at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR total triglycerides as continuous covariates.

    Time frame: Baseline and Weeks 12 and 26.

  126. Change From Baseline to Week 12 in NMR Lipid Fractionation Total Triglycerides

    NMR lipid fractionation was used to assess the change from Baseline in total triglyceride levels at Week 12. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR total triglycerides as continuous covariates.

    Time frame: Baseline and Week 12

  127. Change From Baseline to Week 26 in NMR Lipid Fractionation Total Triglycerides

    NMR lipid fractionation was used to assess the change from Baseline in total triglyceride levels at Week 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR total triglycerides as continuous covariates.

    Time frame: Baseline and Week 26

  128. Change From Baseline in Very Low Density Lipoprotein (VLDL) / Chylomicron Particles Over Time (Grouped Analysis)

    The change from Baseline in levels of total VLDL/chylomicron particles and large VLDL/chylomicron particles was assessed by NMR lipid fractionation at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR VLDL/chylomicron particles as continuous covariates.

    Time frame: Baseline and Weeks 12 and 26

  129. Change From Baseline to Week 12 in VLDL / Chylomicron Particles

    The change from Baseline in levels of total VLDL/chylomicron particles and large VLDL/chylomicron particles was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR VLDL/chylomicron particles as continuous covariates.

    Time frame: Baseline and Week 12

  130. Change From Baseline to Week 26 in VLDL / Chylomicron Particles

    The change from Baseline in levels of total VLDL/chylomicron particles and large VLDL/chylomicron particles was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR VLDL/chylomicron particles as continuous covariates.

    Time frame: Baseline and Week 26

  131. Change From Baseline in VLDL / Chylomicron Triglycerides Over Time (Grouped Analysis)

    The change from Baseline in levels of VLDL/chylomicron triglycerides was assessed by NMR lipid fractionation at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR VLDL/chylomicron triglycerides as continuous covariates.

    Time frame: Baseline and Weeks 12 and 26

  132. Change From Baseline to Week 12 in VLDL / Chylomicron Triglycerides

    The change from Baseline in VLDL/chylomicron triglyceride levels was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR VLDL/chylomicron triglycerides as continuous covariates.

    Time frame: Baseline and Week 12

  133. Change From Baseline to Week 26 in VLDL / Chylomicron Triglycerides

    The change from Baseline in VLDL/chylomicron triglyceride levels was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR VLDL/chylomicron triglycerides as continuous covariates.

    Time frame: Baseline and Week 26

  134. Change From Baseline in VLDL Particles Over Time (Grouped Analysis)

    The change from Baseline in levels of medium VLDL particles and small VLDL particles was assessed by NMR fractionation at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR VLDL particles as continuous covariates.

    Time frame: Baseline and Weeks 12 and 26

  135. Change From Baseline to Week 12 in VLDL Particles

    The change from Baseline in levels of medium VLDL particles and small VLDL particles was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR VLDL particles as continuous covariates.

    Time frame: Baseline and Week 12

  136. Change From Baseline to Week 26 in VLDL Particles

    The change from Baseline in levels of medium VLDL particles and small VLDL particles was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR VLDL particles as continuous covariates

    Time frame: Baseline and Week 26

  137. Change From Baseline in Mean VLDL Particle Size Over Time (Grouped Analysis)

    The change from Baseline in mean VLDL particle size was assessed by NMR lipid fractionation at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline mean VLDL particle size as continuous covariates.

    Time frame: Baseline and Weeks 12 and 26

  138. Change From Baseline to Week 12 in Mean VLDL Particle Size

    The change from Baseline in mean VLDL particle size was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline mean VLDL particle size as continuous covariates.

    Time frame: Baseline and Week 12

  139. Change From Baseline to Week 26 in Mean VLDL Particle Size

    The change from Baseline in mean VLDL particle size was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline mean VLDL particle size as continuous covariates.

    Time frame: Baseline and Week 26

  140. Change From Baseline in Intermediate Density Lipoprotein (IDL) Particles Over Time (Grouped Analysis)

    The change from Baseline in levels of IDL particles was assessed by NMR lipid fractionation at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR IDL particles as continuous covariates.

    Time frame: Baseline and Weeks 12 and 26

  141. Change From Baseline to Week 12 in IDL Particles

    The change from Baseline in levels of IDL particles was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR IDL particles as continuous covariates.

    Time frame: Baseline and Week 12

  142. Change From Baseline to Week 26 in IDL Particles

    The change from Baseline in levels of IDL particles was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR IDL particles as continuous covariates.

    Time frame: Baseline and Week 26

  143. Change From Baseline in Low Density Lipoprotein (LDL) Particles Over Time (Grouped Analysis)

    The change from Baseline in levels of total, large, medium-small, total small and very small LDL particles was assessed by NMR fractionation at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR LDL particles as continuous covariates.

    Time frame: Baseline and Weeks 12 and 26

  144. Change From Baseline to Week 12 in LDL Particles

    The change from Baseline in levels of total, large, medium-small, total small and very small LDL particles was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR LDL particles as continuous covariates.

    Time frame: Baseline and Week 12

  145. Change From Baseline to Week 26 in LDL Particles

    The change from Baseline in levels of total, large, medium-small, total small and very small LDL particles was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR LDL particles as continuous covariates.

    Time frame: Baseline and Week 26

  146. Change From Baseline in Mean LDL Particle Size Over Time (Grouped Analysis)

    The change from Baseline in mean LDL particle size was assessed by NMR lipid fractionation at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline mean LDL particle size as continuous covariates.

    Time frame: Baseline and Weeks 12 and 26

  147. Change From Baseline to Week 12 in Mean LDL Particle Size

    The change from Baseline in mean LDL particle size was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline mean LDL particle size as continuous covariates.

    Time frame: Baseline and Week 12

  148. Change From Baseline to Week 26 in Mean LDL Particle Size

    The change from Baseline in mean LDL particle size was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline mean LDL particle size as continuous covariates.

    Time frame: Baseline and Week 26

  149. Change From Baseline in High Density Lipoprotein (HDL) Particles Over Time (Grouped Analysis)

    The change from Baseline in levels of total, large, medium and small HDL particles was assessed by NMR fractionation at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR HDL particles as continuous covariates.

    Time frame: Baseline and Weeks 12 and 26.

  150. Change From Baseline to Week 12 in HDL Particles

    The change from Baseline in levels of total, large, medium and small HDL particles was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR HDL particles as continuous covariates.

    Time frame: Baseline and Week 12

  151. Change From Baseline to Week 26 in HDL Particles

    The change from Baseline in levels of total, large, medium and small HDL particles was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR HDL particles as continuous covariates.

    Time frame: Baseline and Week 26

  152. Change From Baseline in Mean HDL Particle Size Over Time (Grouped Analysis)

    The change from Baseline in mean HDL particle size was assessed by NMR lipid fractionation at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline mean HDL particle size as continuous covariates.

    Time frame: Baseline and Weeks 12 and 26

  153. Change From Baseline to Week 12 in Mean HDL Particle Size

    The change from Baseline in mean HDL particle size was assessed by NMR lipid fractionation. Least squares means are from are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline mean HDL particle size as continuous covariates.

    Time frame: Baseline and Week 12

  154. Change From Baseline to Week 26 in Mean HDL Particle Size

    The change from Baseline in mean HDL particle size was assessed by NMR lipid fractionation. Least squares means are from are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline mean HDL particle size as continuous covariates.

    Time frame: Baseline and Week 26

07

Results

Posted Apr 4, 2013

Participant flow

Participants took part in the study at 327 investigative sites in 20 countries from 31 May 2006 to 17 March 2008.

Participant flow — Overall Study
MilestonePlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Started129128129130130130129130130129130130
Safety set129128129129130130129130130129130130
Completed7097101931151109411611397112114
Not completed593128371520351417321816
Withdrew: Hyperglycemic rescue411816136519661132
Withdrew: Adverse event312312120754
Withdrew: Protocol violation222855621462
Withdrew: Lost to follow-up422402303201
Withdrew: Withdrawal by subject545625444527
Withdrew: Pregnancy010000000000
Withdrew: Physician decision431211103210
Withdrew: Other000100100110

Outcome measures

PrimaryChange From Baseline to Week 26 in Glycosylated Hemoglobin (HbA1c) (Grouped Analysis)

The change from Baseline to Week 26 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound). The primary analysis compared the groupings (combinations of individual treatment groups) of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone (Pioglitazone Alone).

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · percentage of glycosylated hemoglobin
Change From Baseline to Week 26 in Glycosylated Hemoglobin (HbA1c) (Grouped Analysis)
percentage of glycosylated hemoglobinPioglitazone AloneAlogliptin 12.5 + PioglitazoneAlogliptin 25 + Pioglitazone
Change From Baseline to Week 26 in Glycosylated Hemoglobin (HbA1c) (Grouped Analysis)-0.89 ± 0.046-1.43 ± 0.046-1.42 ± 0.046
Statistical analysis
  • Pioglitazone Alone vs Alogliptin 12.5 + Pioglitazone · ANCOVA · p = <0.001 (For the primary analysis, the overall average HbA1c response of the Alogliptin/pioglitazone combination groups was compared with that of the pioglitazone alone groups at the 2-sided 0.05 significance level with no adjustment for multiple comparisons.) · Ls mean difference: -0.54 · 95% CI -0.67 to -0.41ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HbA1c as continuous covariates.
  • Pioglitazone Alone vs Alogliptin 25 + Pioglitazone · ANCOVA · p = <0.001 · Ls mean difference: -0.53 · 95% CI -0.66 to -0.41ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HbA1c as continuous covariates.
SecondaryChange From Baseline in HbA1c Over Time (Grouped Analysis)

The change from Baseline to Weeks 4, 8, 12, 16 and 20 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound). This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an analysis of covariance (ANCOVA) model with treatment and geographic region as class variables, and baseline metformin dose and HbA1c as continuous covariates.

Time frame:
Baseline and Weeks 4, 8, 12, 16 and 20.
Reported as:
Least squares mean · percentage of glycosylated hemoglobin
Change From Baseline in HbA1c Over Time (Grouped Analysis)
percentage of glycosylated hemoglobinPioglitazone AloneAlogliptin 12.5 + PioglitazoneAlogliptin 25 + Pioglitazone
Week 4 (n=345, 359, 346)-0.32 ± 0.023-0.57 ± 0.023-0.61 ± 0.023
Week 8 (n=376, 385, 377)-0.61 ± 0.034-1.06 ± 0.033-1.09 ± 0.034
Week 12 (n=376, 385, 377)-0.81 ± 0.039-1.29 ± 0.039-1.38 ± 0.039
Week 16 (n=376, 385, 377)-0.92 ± 0.041-1.44 ± 0.041-1.49 ± 0.041
Week 20 (n=376, 385, 377)-0.92 ± 0.043-1.46 ± 0.042-1.51 ± 0.043
SecondaryChange From Baseline to Week 4 in HbA1c

The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at week 4. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HbA1c as continuous covariates.

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · percentage of glycosylated hemoglobin
Change From Baseline to Week 4 in HbA1c
percentage of glycosylated hemoglobinPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 4 in HbA1c-0.22 ± 0.039-0.46 ± 0.040-0.51 ± 0.041-0.32 ± 0.040-0.53 ± 0.039-0.61 ± 0.040-0.24 ± 0.040-0.60 ± 0.039-0.60 ± 0.039-0.40 ± 0.040-0.58 ± 0.040-0.63 ± 0.040
SecondaryChange From Baseline to Week 8 in HbA1c

The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at week 8. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HbA1c as continuous covariates.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · percentage of glycosylated hemoglobin
Change From Baseline to Week 8 in HbA1c
percentage of glycosylated hemoglobinPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 mg + Pioglitazone 30 mgAlogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45 mgAlogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 8 in HbA1c-0.30 ± 0.058-0.75 ± 0.059-0.80 ± 0.059-0.50 ± 0.058-1.01 ± 0.058-1.04 ± 0.058-0.57 ± 0.059-1.05 ± 0.058-1.02 ± 0.059-0.76 ± 0.058-1.11 ± 0.058-1.20 ± 0.058
SecondaryChange From Baseline to Week 12 in HbA1c

The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at week 12. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HbA1c as continuous covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percentage of glycosylated hemoglobin
Change From Baseline to Week 12 in HbA1c
percentage of glycosylated hemoglobinPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 mg + Pioglitazone 30 mgAlogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45 mgAlogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 12 in HbA1c-0.28 ± 0.067-0.84 ± 0.069-0.92 ± 0.068-0.65 ± 0.067-1.24 ± 0.066-1.26 ± 0.067-0.77 ± 0.068-1.29 ± 0.067-1.33 ± 0.068-1.02 ± 0.067-1.34 ± 0.067-1.53 ± 0.067
SecondaryChange From Baseline to Week 16 in HbA1c

The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at week 16. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HbA1c as continuous covariates.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · percentage of glycosylated hemoglobin
Change From Baseline to Week 16 in HbA1c
percentage of glycosylated hemoglobinPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 mg + Pioglitazone 30 mgAlogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45 mgAlogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 16 in HbA1c-0.27 ± 0.071-0.82 ± 0.072-1.03 ± 0.072-0.74 ± 0.071-1.36 ± 0.070-1.36 ± 0.071-0.91 ± 0.072-1.42 ± 0.071-1.45 ± 0.072-1.12 ± 0.071-1.53 ± 0.071-1.66 ± 0.071
SecondaryChange From Baseline to Week 20 in HbA1c

The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at week 20. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HbA1c as continuous covariates.

Time frame:
Baseline and Week 20
Reported as:
Least squares mean · percentage of glycosylated hemoglobin
Change From Baseline to Week 20 in HbA1c
percentage of glycosylated hemoglobinPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 mg + Pioglitazone 30 mgAlogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45 mgAlogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 20 in HbA1c-0.24 ± 0.074-0.75 ± 0.075-0.99 ± 0.075-0.75 ± 0.074-1.39 ± 0.073-1.37 ± 0.074-0.90 ± 0.075-1.43 ± 0.074-1.49 ± 0.075-1.10 ± 0.074-1.57 ± 0.074-1.66 ± 0.074
SecondaryChange From Baseline in Fasting Plasma Glucose Over Time (Grouped Analysis)

The change from Baseline in fasting plasma glucose was assessed at weeks 1, 2, 4, 8, 12, 16, 20 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline fasting plasma glucose as covariates.

Time frame:
Baseline and Weeks 1, 2, 4, 8, 12, 16, 20 and 26.
Reported as:
Least squares mean · mg/dL
Change From Baseline in Fasting Plasma Glucose Over Time (Grouped Analysis)
mg/dLPioglitazone AloneAlogliptin 12.5 + PioglitazoneAlogliptin 25 + Pioglitazone
Week 1 (n=358, 355, 354)-4.1 ± 1.56-22.6 ± 1.57-23.1 ± 1.57
Week 2 (n=379, 383, 381)-11.3 ± 1.62-30.3 ± 1.61-31.6 ± 1.62
Week 4 (n=381, 386, 383)-19.9 ± 1.67-36.8 ± 1.66-39.8 ± 1.67
Week 8 (n=381, 386, 383)-27.3 ± 1.77-42.3 ± 1.76-45.2 ± 1.77
Week 12 (n=381, 386, 383)-30.3 ± 1.84-45.0 ± 1.83-47.6 ± 1.83
Week 16 (n=381, 386, 383)-27.9 ± 1.86-43.7 ± 1.85-45.4 ± 1.86
Week 20 (n=381, 386, 383)-28.1 ± 2.00-43.6 ± 1.99-45.0 ± 1.99
Week 26 (n=381, 386, 383)-28.3 ± 2.03-45.2 ± 2.02-44.2 ± 2.03
SecondaryChange From Baseline to Week 1 in Fasting Plasma Glucose

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline fasting plasma glucose as covariates.

Time frame:
Baseline and Week 1
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 1 in Fasting Plasma Glucose
mg/dLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 1 in Fasting Plasma Glucose1.8 ± 2.67-14.5 ± 2.77-18.6 ± 2.73-6.1 ± 2.70-21.3 ± 2.69-20.9 ± 2.660.4 ± 2.73-23.2 ± 2.71-23.2 ± 2.72-6.7 ± 2.69-23.2 ± 2.76-25.0 ± 2.78
SecondaryChange From Baseline to Week 2 in Fasting Plasma Glucose

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline fasting plasma glucose as covariates.

Time frame:
Baseline and Week 2
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 2 in Fasting Plasma Glucose
mg/dLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 2 in Fasting Plasma Glucose4.8 ± 2.78-21.9 ± 2.88-18.9 ± 2.82-10.4 ± 2.80-30.1 ± 2.80-31.7 ± 2.78-4.3 ± 2.83-30.0 ± 2.79-31.3 ± 2.81-19.3 ± 2.79-30.8 ± 2.79-31.7 ± 2.81
SecondaryChange From Baseline to Week 4 in Fasting Plasma Glucose

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline fasting plasma glucose as covariates.

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 4 in Fasting Plasma Glucose
mg/dLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 4 in Fasting Plasma Glucose3.8 ± 2.87-20.4 ± 2.95-22.8 ± 2.92-20.2 ± 2.90-35.3 ± 2.87-37.3 ± 2.86-13.4 ± 2.92-37.4 ± 2.88-36.0 ± 2.91-26.1 ± 2.87-37.8 ± 2.89-46.2 ± 2.89
SecondaryChange From Baseline to Week 8 in Fasting Plasma Glucose

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline fasting plasma glucose as covariates.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 8 in Fasting Plasma Glucose
mg/dLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 8 in Fasting Plasma Glucose5.7 ± 3.05-19.5 ± 3.14-19.3 ± 3.09-22.2 ± 3.07-42.3 ± 3.05-39.3 ± 3.04-24.0 ± 3.10-40.5 ± 3.05-44.1 ± 3.08-35.6 ± 3.05-44.0 ± 3.06-52.3 ± 3.07
SecondaryChange From Baseline to Week 12 in Fasting Plasma Glucose

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline fasting plasma glucose as covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 12 in Fasting Plasma Glucose
mg/dLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 12 in Fasting Plasma Glucose3.4 ± 3.16-19.3 ± 3.25-23.3 ± 3.19-23.0 ± 3.18-42.9 ± 3.16-42.5 ± 3.14-26.6 ± 3.21-42.8 ± 3.16-49.0 ± 3.19-41.3 ± 3.16-49.2 ± 3.17-51.4 ± 3.18
SecondaryChange From Baseline to Week 16 in Fasting Plasma Glucose

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline fasting plasma glucose as covariates.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 16 in Fasting Plasma Glucose
mg/dLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 16 in Fasting Plasma Glucose1.4 ± 3.20-16.2 ± 3.29-22.6 ± 3.24-21.2 ± 3.22-41.6 ± 3.20-39.1 ± 3.19-26.3 ± 3.25-41.5 ± 3.20-43.4 ± 3.24-36.3 ± 3.20-47.9 ± 3.21-53.8 ± 3.22
SecondaryChange From Baseline to Week 20 in Fasting Plasma Glucose

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline fasting plasma glucose as covariates.

Time frame:
Baseline and Week 20
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 20 in Fasting Plasma Glucose
mg/dLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 20 in Fasting Plasma Glucose6.7 ± 3.43-8.7 ± 3.53-23.5 ± 3.48-22.4 ± 3.46-43.0 ± 3.43-39.3 ± 3.42-26.3 ± 3.49-41.1 ± 3.44-43.1 ± 3.47-35.7 ± 3.43-46.8 ± 3.45-52.4 ± 3.46
SecondaryChange From Baseline to Week 26 in Fasting Plasma Glucose

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline fasting plasma glucose as covariates.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 26 in Fasting Plasma Glucose
mg/dLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 26 in Fasting Plasma Glucose6.5 ± 3.50-13.2 ± 3.59-18.6 ± 3.54-23.6 ± 3.52-42.0 ± 3.50-38.0 ± 3.48-28.8 ± 3.55-42.2 ± 3.50-41.7 ± 3.54-32.4 ± 3.49-51.3 ± 3.51-52.7 ± 3.52
SecondaryPercentage of Participants With Marked Hyperglycemia (Grouped Analysis)

Marked hyperglycemia is defined as fasting plasma glucose greater than or equal to 200 mg/dL (11.10 mmol/L). This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone.

Time frame:
From Week 1 to Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With Marked Hyperglycemia (Grouped Analysis)
percentage of participantsPioglitazone AloneAlogliptin 12.5 + PioglitazoneAlogliptin 25 + Pioglitazone
Percentage of Participants With Marked Hyperglycemia (Grouped Analysis)39.424.622.1
SecondaryPercentage of Participants With Marked Hyperglycemia

Marked hyperglycemia is defined as fasting plasma glucose greater than or equal to 200 mg/dL (11.10 mmol/L).

Time frame:
From Week 1 to Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With Marked Hyperglycemia
percentage of participantsPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Percentage of Participants With Marked Hyperglycemia60.542.639.737.827.122.339.226.423.641.120.320.5
SecondaryPercentage of Participants Meeting Rescue Criteria (Grouped Analysis)

Rescue was defined as meeting 1 of the following criteria, confirmed by a 2nd sample drawn within 5 days of the first and analyzed by the central laboratory: 1. After the Week 1 Visit but prior to the Week 4 Visit: a single fasting plasma glucose ≥300 mg/dL; 2. From the Week 4 Visit but prior to the Week 8 Visit: a single fasting plasma glucose ≥275 mg/dL; 3. From the Week 8 Visit but prior to the Week 12 Visit: a single fasting plasma glucose ≥250 mg/dL; 4. From the Week 12 Visit through the End-of-Treatment Visit: HbA1c ≥8.5% and ≤0.5% reduction in HbA1c as compared with Baseline HbA1c.

Time frame:
From Week 1 to Week 26.
Reported as:
Number · percentage of participants
Percentage of Participants Meeting Rescue Criteria (Grouped Analysis)
percentage of participantsPioglitazone AloneAlogliptin 12.5 + PioglitazoneAlogliptin 25 + Pioglitazone
Percentage of Participants Meeting Rescue Criteria (Grouped Analysis)11.43.93.4
SecondaryPercentage of Participants Meeting Rescue Criteria

Rescue was defined as meeting 1 of the following criteria, confirmed by a 2nd sample drawn within 5 days of the first and analyzed by the central laboratory: 1. After the Week 1 Visit but prior to the Week 4 Visit: a single fasting plasma glucose ≥300 mg/dL; 2. From the Week 4 Visit but prior to the Week 8 Visit: a single fasting plasma glucose ≥275 mg/dL; 3. From the Week 8 Visit but prior to the Week 12 Visit: a single fasting plasma glucose ≥250 mg/dL; 4. From the Week 12 Visit through the End-of-Treatment Visit: HbA1c ≥8.5% and ≤0.5% reduction in HbA1c as compared with Baseline HbA1c.

Time frame:
From Week 1 to Week 26
Reported as:
Number · percentage of participants
Percentage of Participants Meeting Rescue Criteria
percentage of participantsPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Percentage of Participants Meeting Rescue Criteria32.814.512.810.24.73.915.44.84.98.72.41.6
SecondaryPercentage of Participants With Glycosylated Hemoglobin ≤ 6.5% (Grouped Analysis)

Clinical response at Week 26 was assessed by the percentage of participants with HbA1c less than or equal to 6.5%. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With Glycosylated Hemoglobin ≤ 6.5% (Grouped Analysis)
percentage of participantsPioglitazone AloneAlogliptin 12.5 + PioglitazoneAlogliptin 25 + Pioglitazone
Percentage of Participants With Glycosylated Hemoglobin ≤ 6.5% (Grouped Analysis)12.427.929.2
SecondaryPercentage of Participants With Glycosylated Hemoglobin ≤ 6.5%

Clinical response at Week 26 was assessed by the percentage of participants with HbA1c less than or equal to 6.5%.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With Glycosylated Hemoglobin ≤ 6.5%
percentage of participantsPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Percentage of Participants With Glycosylated Hemoglobin ≤ 6.5%0.88.612.46.221.524.611.630.030.019.432.333.1
SecondaryPercentage of Participants With Glycosylated Hemoglobin ≤ 7.0% (Grouped Analysis)

Clinical response at Week 26 was assessed by the percentage of participants with HbA1c less than or equal to 7%. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With Glycosylated Hemoglobin ≤ 7.0% (Grouped Analysis)
percentage of participantsPioglitazone AloneAlogliptin 12.5 + PioglitazoneAlogliptin 25 + Pioglitazone
Percentage of Participants With Glycosylated Hemoglobin ≤ 7.0% (Grouped Analysis)30.554.655.9
SecondaryPercentage of Participants With Glycosylated Hemoglobin ≤ 7%

Clinical response at Week 26 was assessed by the percentage of participants with HbA1c less than or equal to 7%.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With Glycosylated Hemoglobin ≤ 7%
percentage of participantsPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Percentage of Participants With Glycosylated Hemoglobin ≤ 7%6.222.727.125.649.254.629.553.153.136.461.560.0
SecondaryPercentage of Participants With Glycosylated Hemoglobin ≤ 7.5% (Grouped Analysis)

Clinical response at Week 26 was assessed by the percentage of participants with HbA1c less than or equal to 7.5%. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With Glycosylated Hemoglobin ≤ 7.5% (Grouped Analysis)
percentage of participantsPioglitazone AloneAlogliptin 12.5 + PioglitazoneAlogliptin 25 + Pioglitazone
Percentage of Participants With Glycosylated Hemoglobin ≤ 7.5% (Grouped Analysis)54.877.474.1
SecondaryPercentage of Participants With Glycosylated Hemoglobin ≤ 7.5%

Clinical response at Week 26 was assessed by the percentage of participants with HbA1c less than or equal to 7.5%.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With Glycosylated Hemoglobin ≤ 7.5%
percentage of participantsPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Percentage of Participants With Glycosylated Hemoglobin ≤ 7.5%24.838.355.051.977.771.555.873.872.356.680.878.5
SecondaryPercentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 0.5% (Grouped Analysis)

Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 0.5%. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone.

Time frame:
Baseline and Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 0.5% (Grouped Analysis)
percentage of participantsPioglitazone AloneAlogliptin 12.5 + PioglitazoneAlogliptin 25 + Pioglitazone
Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 0.5% (Grouped Analysis)67.285.683.3
SecondaryPercentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 0.5%

Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 0.5%.

Time frame:
Baseline and Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 0.5%
percentage of participantsPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 0.5%31.857.866.761.286.279.268.286.983.872.183.886.9
SecondaryPercentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 1% (Grouped Analysis)

Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 1%. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone.

Time frame:
Baseline and Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 1% (Grouped Analysis)
percentage of participantsPioglitazone AloneAlogliptin 12.5 + PioglitazoneAlogliptin 25 + Pioglitazone
Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 1% (Grouped Analysis)45.771.869.5
SecondaryPercentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 1%

Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 1%.

Time frame:
Baseline and Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 1%
percentage of participantsPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 1%16.333.647.336.469.266.946.573.169.254.373.172.3
SecondaryPercentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 1.5% (Grouped Analysis)

Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 1.5%. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone.

Time frame:
Baseline and Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 1.5% (Grouped Analysis)
percentage of participantsPioglitazone AloneAlogliptin 12.5 + PioglitazoneAlogliptin 25 + Pioglitazone
Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 1.5% (Grouped Analysis)27.645.950.3
SecondaryPercentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 1.5%

Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 1.5%.

Time frame:
Baseline and Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 1.5%
percentage of participantsPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 1.5%5.415.628.721.741.546.227.145.446.234.150.858.5
PrimaryChange From Baseline to Week 26 in HbA1c

The change from Baseline to Week 26 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound).

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · percentage of glycosylated hemoglobin
Change From Baseline to Week 26 in HbA1c
percentage of glycosylated hemoglobinPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 26 in HbA1c-0.13 ± 0.080-0.64 ± 0.081-0.90 ± 0.081-0.75 ± 0.079-1.34 ± 0.078-1.27 ± 0.079-0.92 ± 0.081-1.39 ± 0.079-1.39 ± 0.080-1.00 ± 0.080-1.55 ± 0.079-1.60 ± 0.080
Statistical analysis
  • Alogliptin 12.5 + Placebo vs Alogliptin 12.5 + Pioglitazone 15 · ANCOVA · p = <0.001 (As a supportive analysis, each of the individual combination treatment groups was compared with the component treatment groups receiving aloliptin alone and pioglitazone alone at the 2-sided 0.05 significance level with no multiplicity adjustment.) · Ls mean difference: -0.70 · 95% CI -0.93 to -0.48ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HbA1c as continuous covariates.
  • Placebo + Pioglitazone 15 vs Alogliptin 12.5 + Pioglitazone 15 · ANCOVA · p = <0.001 · Ls mean difference: -0.59 · 95% CI -0.81 to -0.38ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HbA1c as continuous covariates.
  • Alogliptin 25 + Placebo vs Alogliptin 25 + Pioglitazone 15 · ANCOVA · p = 0.001 · Ls mean difference: -0.37 · 95% CI -0.59 to -0.15ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HbA1c as continuous covariates.
  • Placebo + Pioglitazone 15 vs Alogliptin 25 + Pioglitazone 15 · ANCOVA · p = <0.001 · Ls mean difference: -0.52 · 95% CI -0.74 to -0.30ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HbA1c as continuous covariates.
  • Alogliptin 12.5 + Placebo vs Alogliptin 12.5 + Pioglitazone 30 · ANCOVA · p = <0.001 · Ls mean difference: -0.76 · 95% CI -0.98 to -0.53ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HbA1c as continuous covariates.
  • Placebo + Pioglitazone 30 vs Alogliptin 12.5 + Pioglitazone 30 · ANCOVA · p = <0.001 · Ls mean difference: -0.47 · 95% CI -0.70 to -0.25ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HbA1c as continuous covariates.
  • Alogliptin 25 + Placebo vs Alogliptin 25 + Pioglitazone 30 · ANCOVA · p = <0.001 · Ls mean difference: -0.49 · 95% CI -0.71 to -0.27ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HbA1c as continuous covariates.
  • Placebo + Pioglitazone 30 vs Alogliptin 25 + Pioglitazone 30 · ANCOVA · p = <0.001 · Ls mean difference: -0.47 · 95% CI -0.70 to -0.25ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HbA1c as continuous covariates.
  • Alogliptin 12.5 + Placebo vs Alogliptin 12.5 + Pioglitazone 45 · ANCOVA · p = <0.001 · Ls mean difference: -0.91 · 95% CI -1.13 to -0.68ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HbA1c as continuous covariates.
  • Placebo + Pioglitazone 45 vs Alogliptin 12.5 + Pioglitazone 45 · ANCOVA · p = <0.001 · Ls mean difference: -0.55 · 95% CI -0.77 to -0.33ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HbA1c as continuous covariates.
  • Alogliptin 25 + Placebo vs Alogliptin 25 + Pioglitazone 45 · ANCOVA · p = <0.001 · Ls mean difference: -0.70 · 95% CI -0.92 to -0.48ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HbA1c as continuous covariates.
  • Placebo + Pioglitazone 45 vs Alogliptin 25 + Pioglitazone 45 · ANCOVA · p = <0.001 · Ls mean difference: -0.61 · 95% CI -0.83 to -0.39ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HbA1c as continuous covariates.
SecondaryPercentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 2.0% (Grouped Analysis)

Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 2.0%. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone.

Time frame:
Baseline and Week 26.
Reported as:
Number · percentage of participants
Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 2.0% (Grouped Analysis)
percentage of participantsPioglitazone AloneAlogliptin 12.5 + PioglitazoneAlogliptin 25 + Pioglitazone
Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 2.0% (Grouped Analysis)11.125.427.7
SecondaryPercentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 2%

Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 2%.

Time frame:
Baseline and Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 2%
percentage of participantsPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 2%1.67.811.67.023.121.59.322.326.217.130.835.4
SecondaryChange From Baseline in Fasting Proinsulin Over Time (Grouped Analysis)

Proinsulin is a precursor to insulin, and was measured as an indicator of pancreatic function. The change from Baseline in fasting proinsulin was assessed at Weeks 4, 8, 12, 16, 20 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and proinsulin as continuous covariates.

Time frame:
Baseline and Weeks 4, 8, 12, 16, 20 and 26.
Reported as:
Least squares mean · pmol/L
Change From Baseline in Fasting Proinsulin Over Time (Grouped Analysis)
pmol/LPioglitazone AloneAlogliptin 12.5 + PioglitazoneAlogliptin 25 + Pioglitazone
Week 4 (n=328, 319, 327)-6.2 ± 0.81-10.3 ± 0.82-10.1 ± 0.81
Week 8 (n=357, 347, 358)-7.2 ± 0.87-11.3 ± 0.88-11.3 ± 0.87
Week 12 (n=357, 347, 358)-8.2 ± 0.91-11.6 ± 0.93-11.6 ± 0.91
Week 16 (n=358, 348, 358)-7.2 ± 0.92-12.2 ± 0.94-11.3 ± 0.92
Week 20 (n=358, 349, 359)-6.6 ± 1.08-10.4 ± 1.09-10.7 ± 1.08
Week 26 (n=358, 349, 359)-5.3 ± 1.09-10.6 ± 1.11-9.5 ± 1.09
SecondaryChange From Baseline to Week 4 in Fasting Proinsulin

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin as continuous covariates.

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · pmol/L
Change From Baseline to Week 4 in Fasting Proinsulin
pmol/LPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 4 in Fasting Proinsulin-0.1 ± 1.36-4.7 ± 1.39-2.3 ± 1.41-4.8 ± 1.42-9.9 ± 1.41-8.9 ± 1.41-6.7 ± 1.40-9.6 ± 1.43-9.5 ± 1.37-7.2 ± 1.39-11.3 ± 1.43-11.7 ± 1.44
SecondaryChange From Baseline to Week 8 in Fasting Proinsulin

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin as continuous covariates.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · pmol/L
Change From Baseline to Week 8 in Fasting Proinsulin
pmol/LPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 8 in Fasting Proinsulin0.7 ± 1.480.2 ± 1.50-2.6 ± 1.48-3.8 ± 1.49-11.1 ± 1.50-10.7 ± 1.50-8.8 ± 1.52-11.8 ± 1.54-9.4 ± 1.50-9.0 ± 1.50-11.0 ± 1.53-13.8 ± 1.50
SecondaryChange From Baseline to Week 12 in Fasting Proinsulin

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin as continuous covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · pmol/L
Change From Baseline to Week 12 in Fasting Proinsulin
pmol/LPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 12 in Fasting Proinsulin-1.0 ± 1.56-0.7 ± 1.57-2.3 ± 1.56-5.3 ± 1.57-10.1 ± 1.58-8.8 ± 1.58-11.2 ± 1.60-12.1 ± 1.63-12.7 ± 1.58-8.1 ± 1.58-12.7 ± 1.61-13.2 ± 1.58
SecondaryChange From Baseline to Week 16 in Fasting Proinsulin

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin as continuous covariates.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · pmol/L
Change From Baseline to Week 16 in Fasting Proinsulin
pmol/LPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 16 in Fasting Proinsulin-3.0 ± 1.580.0 ± 1.60-2.3 ± 1.58-3.7 ± 1.59-11.0 ± 1.60-8.4 ± 1.60-10.0 ± 1.62-12.6 ± 1.65-11.2 ± 1.60-8.0 ± 1.60-13.0 ± 1.63-14.4 ± 1.60
SecondaryChange From Baseline to Week 20 in Fasting Proinsulin

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin as continuous covariates.

Time frame:
Baseline and Week 20
Reported as:
Least squares mean · pmol/L
Change From Baseline to Week 20 in Fasting Proinsulin
pmol/LPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 20 in Fasting Proinsulin-0.9 ± 1.851.5 ± 1.86-3.0 ± 1.84-3.4 ± 1.86-11.2 ± 1.86-8.7 ± 1.86-9.3 ± 1.89-10.0 ± 1.92-10.7 ± 1.87-7.1 ± 1.86-10.2 ± 1.90-12.5 ± 1.87
SecondaryChange From Baseline to Week 26 in Fasting Proinsulin

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin as continuous covariates.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · pmol/L
Change From Baseline to Week 26 in Fasting Proinsulin
pmol/LPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 26 in Fasting Proinsulin1.2 ± 1.870.7 ± 1.88-3.3 ± 1.86-3.5 ± 1.88-10.9 ± 1.88-7.2 ± 1.88-8.4 ± 1.91-8.9 ± 1.95-8.8 ± 1.89-4.1 ± 1.89-12.1 ± 1.93-12.6 ± 1.89
SecondaryChange From Baseline in Insulin Over Time (Grouped Analysis)

The change from Baseline in fasting insulin was assessed at Weeks 4, 8, 12, 16, 20 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline insulin as continuous covariates.

Time frame:
Baseline and Weeks 4, 8, 12, 16, 20 and 26.
Reported as:
Least squares mean · µIU/mL
Change From Baseline in Insulin Over Time (Grouped Analysis)
µIU/mLPioglitazone AloneAlogliptin 12.5 + PioglitazoneAlogliptin 25 + Pioglitazone
Week 4 (n=325, 318, 326)-2.29 ± 0.440-2.11 ± 0.445-2.19 ± 0.440
Week 8 (n=355, 346, 356)-2.35 ± 0.535-2.44 ± 0.542-2.36 ± 0.534
Week 12 (n=355, 347, 356)-2.62 ± 0.498-1.73 ± 0.503-2.62 ± 0.497
Week 16 (n=356, 348, 356)-2.19 ± 0.488-2.60 ± 0.494-2.48 ± 0.488
Week 20 (n=356, 349, 357)-2.35 ± 0.511-1.91 ± 0.516-2.06 ± 0.510
Week 26 (n=356, 349, 357)-1.74 ± 1.212-2.05 ± 1.225-1.66 ± 1.210
SecondaryChange From Baseline to Week 4 in Insulin Levels

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline insulin as continuous covariates.

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · µIU/mL
Change From Baseline to Week 4 in Insulin Levels
µIU/mLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 4 in Insulin Levels1.06 ± 0.737-0.33 ± 0.7562.31 ± 0.771-1.68 ± 0.767-3.03 ± 0.760-1.86 ± 0.763-2.43 ± 0.760-1.45 ± 0.779-2.05 ± 0.743-2.76 ± 0.760-1.85 ± 0.774-2.65 ± 0.778
SecondaryChange From Baseline to Week 8 in Insulin Levels

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline insulin as continuous covariates.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · µIU/mL
Change From Baseline to Week 8 in Insulin Levels
µIU/mLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 8 in Insulin Levels-0.46 ± 0.9121.80 ± 0.9231.69 ± 0.909-1.47 ± 0.916-2.21 ± 0.923-2.78 ± 0.923-2.74 ± 0.935-3.15 ± 0.953-1.20 ± 0.927-2.83 ± 0.927-1.96 ± 0.939-3.09 ± 0.924
SecondaryChange From Baseline to Week 12 in Insulin Levels

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline insulin as continuous covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · µIU/mL
Change From Baseline to Week 12 in Insulin Levels
µIU/mLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 12 in Insulin Levels0.06 ± 0.8491.79 ± 0.8591.93 ± 0.846-1.29 ± 0.852-1.47 ± 0.859-2.01 ± 0.859-3.61 ± 0.870-1.36 ± 0.882-2.83 ± 0.863-2.95 ± 0.863-2.35 ± 0.874-3.01 ± 0.859
SecondaryChange From Baseline to Week 16 in Insulin Levels

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline insulin as continuous covariates.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · µIU/mL
Change From Baseline to Week 16 in Insulin Levels
µIU/mLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 16 in Insulin Levels0.34 ± 0.8331.22 ± 0.8431.83 ± 0.830-0.63 ± 0.836-2.28 ± 0.840-1.11 ± 0.843-3.46 ± 0.851-2.50 ± 0.866-2.82 ± 0.847-2.48 ± 0.847-3.00 ± 0.858-3.52 ± 0.844
SecondaryChange From Baseline to Week 20 in Insulin Levels

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline insulin as continuous covariates.

Time frame:
Baseline and Week 20
Reported as:
Least squares mean · µIU/mL
Change From Baseline to Week 20 in Insulin Levels
µIU/mLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 20 in Insulin Levels0.18 ± 0.8732.03 ± 0.8830.76 ± 0.869-0.66 ± 0.876-2.35 ± 0.876-0.90 ± 0.880-3.29 ± 0.891-2.20 ± 0.907-2.29 ± 0.887-3.12 ± 0.887-1.16 ± 0.899-3.01 ± 0.884
SecondaryChange From Baseline to Week 26 in Insulin Levels

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline insulin as continuous covariates.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · µIU/mL
Change From Baseline to Week 26 in Insulin Levels
µIU/mLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 26 in Insulin Levels6.78 ± 2.0711.33 ± 2.0961.43 ± 2.063-0.78 ± 2.078-3.05 ± 2.078-0.76 ± 2.087-2.56 ± 2.114-0.76 ± 2.152-1.42 ± 2.105-1.88 ± 2.105-2.33 ± 2.132-2.79 ± 2.096
SecondaryChange From Baseline in Proinsulin/Insulin Ratio Over Time (Grouped Analysis)

The ratio of proinsulin to insulin was calculated as proinsulin (pmol/L) / insulin (μIU/mL) at weeks 4, 8, 12, 16, 20 and 26 relative to the Baseline value. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin/insulin ratio as continuous covariates.

Time frame:
Baseline and Weeks 4, 8, 12, 16, 20 and 26.
Reported as:
Least squares mean · ratio
Change From Baseline in Proinsulin/Insulin Ratio Over Time (Grouped Analysis)
ratioPioglitazone AloneAlogliptin 12.5 + PioglitazoneAlogliptin 25 + Pioglitazone
Week 4 (n=325, 315, 326)-0.021 ± 0.0088-0.078 ± 0.0089-0.057 ± 0.0088
Week 8 (n=355, 344, 356)-0.019 ± 0.0084-0.079 ± 0.0086-0.081 ± 0.0084
Week 12 (n=355, 345, 356)-0.042 ± 0.0083-0.086 ± 0.0084-0.082 ± 0.0083
Week 16 (n=356, 346, 356)-0.033 ± 0.0077-0.091 ± 0.0078-0.077 ± 0.0077
Week 20 (n=356, 347, 357)-0.034 ± 0.0076-0.088 ± 0.0077-0.078 ± 0.0076
Week 26 (n=356, 347, 357)-0.027 ± 0.0088-0.087 ± 0.0090-0.076 ± 0.0088
SecondaryChange From Baseline to Week 4 in Proinsulin/Insulin Ratio

The ratio of proinsulin to insulin was calculated as proinsulin (pmol/L) / insulin (μIU/mL). Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin/insulin ratio as continuous covariates.

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · ratio
Change From Baseline to Week 4 in Proinsulin/Insulin Ratio
ratioPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 4 in Proinsulin/Insulin Ratio-0.015 ± 0.0147-0.039 ± 0.0151-0.058 ± 0.0154-0.029 ± 0.0153-0.054 ± 0.0153-0.054 ± 0.0153-0.023 ± 0.0152-0.068 ± 0.0157-0.045 ± 0.0149-0.009 ± 0.0152-0.111 ± 0.0155-0.072 ± 0.0156
SecondaryChange From Baseline to Week 8 in Proinsulin/Insulin Ratio

The ratio of proinsulin to insulin was calculated as proinsulin (pmol/L) / insulin (μIU/mL). Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin/insulin ratio as continuous covariates.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · ratio
Change From Baseline to Week 8 in Proinsulin/Insulin Ratio
ratioPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 8 in Proinsulin/Insulin Ratio0.005 ± 0.0144-0.025 ± 0.0146-0.045 ± 0.0143-0.007 ± 0.0144-0.086 ± 0.0146-0.077 ± 0.0146-0.036 ± 0.0148-0.054 ± 0.0152-0.072 ± 0.0146-0.013 ± 0.0146-0.098 ± 0.0148-0.093 ± 0.0146
SecondaryChange From Baseline to Week 12 in Proinsulin/Insulin Ratio

The ratio of proinsulin to insulin was calculated as proinsulin (pmol/L) / insulin (μIU/mL). Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin/insulin ratio as continuous covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · ratio
Change From Baseline to Week 12 in Proinsulin/Insulin Ratio
ratioPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 12 in Proinsulin/Insulin Ratio-0.006 ± 0.0142-0.024 ± 0.0144-0.041 ± 0.0141-0.041 ± 0.0142-0.073 ± 0.0144-0.056 ± 0.0144-0.063 ± 0.0146-0.072 ± 0.0149-0.088 ± 0.0144-0.021 ± 0.0144-0.112 ± 0.0146-0.101 ± 0.0144
SecondaryChange From Baseline to Week 16 in Proinsulin/Insulin Ratio

The ratio of proinsulin to insulin was calculated as proinsulin (pmol/L) / insulin (μIU/mL). Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin/insulin ratio as continuous covariates.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · ratio
Change From Baseline to Week 16 in Proinsulin/Insulin Ratio
ratioPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 16 in Proinsulin/Insulin Ratio-0.026 ± 0.0132-0.036 ± 0.0133-0.046 ± 0.0131-0.035 ± 0.0132-0.078 ± 0.0133-0.066 ± 0.0134-0.035 ± 0.0135-0.094 ± 0.0138-0.061 ± 0.0134-0.030 ± 0.0134-0.102 ± 0.0136-0.104 ± 0.0133
SecondaryChange From Baseline to Week 20 in Proinsulin/Insulin Ratio

The ratio of proinsulin to insulin was calculated as proinsulin (pmol/L) / insulin (μIU/mL). Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin/insulin ratio as continuous covariates.

Time frame:
Baseline and Week 20
Reported as:
Least squares mean · ratio
Change From Baseline to Week 20 in Proinsulin/Insulin Ratio
ratioPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 20 in Proinsulin/Insulin Ratio-0.007 ± 0.0131-0.014 ± 0.0132-0.046 ± 0.0130-0.039 ± 0.0131-0.081 ± 0.0131-0.065 ± 0.0132-0.042 ± 0.0133-0.085 ± 0.0137-0.077 ± 0.0133-0.020 ± 0.0133-0.099 ± 0.0134-0.092 ± 0.0132
SecondaryChange From Baseline to Week 26 in Proinsulin/Insulin Ratio

The ratio of proinsulin to insulin was calculated as proinsulin (pmol/L) / insulin (μIU/mL). Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin/insulin ratio as continuous covariates.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · ratio
Change From Baseline to Week 26 in Proinsulin/Insulin Ratio
ratioPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 26 in Proinsulin/Insulin Ratio-0.007 ± 0.0151-0.001 ± 0.0153-0.064 ± 0.0151-0.038 ± 0.0152-0.071 ± 0.0152-0.063 ± 0.0152-0.030 ± 0.0154-0.081 ± 0.0159-0.072 ± 0.0154-0.014 ± 0.0154-0.109 ± 0.0156-0.092 ± 0.0153
SecondaryChange From Baseline in C-peptide Over Time (Grouped Analysis)

C-peptide is a byproduct created when the hormone insulin is produced and is measured by a blood test. Change from Baseline was assessed at Weeks 4, 8, 12, 16, 20 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline C-peptide as continuous covariates.

Time frame:
Baseline and Weeks 4, 8, 12, 16, 20 and 26.
Reported as:
Least squares mean · ng/mL
Change From Baseline in C-peptide Over Time (Grouped Analysis)
ng/mLPioglitazone AloneAlogliptin 12.5 + PioglitazoneAlogliptin 25 + Pioglitazone
Week 4 (n=335, 335, 336)-0.292 ± 0.0417-0.255 ± 0.0417-0.282 ± 0.0416
Week 8 (n=367, 366, 371)-0.356 ± 0.0464-0.327 ± 0.0464-0.311 ± 0.0461
Week 12 (n=367, 369, 374)-0.268 ± 0.0781-0.249 ± 0.0779-0.334 ± 0.0774
Week 16 (n=369, 374, 374)-0.352 ± 0.0456-0.343 ± 0.0453-0.333 ± 0.0453
Week 20 (n=369, 375, 375)-0.360 ± 0.0465-0.350 ± 0.0461-0.293 ± 0.0461
Week 26 (n=371, 378, 375)-0.341 ± 0.0460-0.346 ± 0.0456-0.326 ± 0.0457
SecondaryChange From Baseline to Week 4 in C-peptide Levels

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline C-peptide as continuous covariates.

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · ng/mL
Change From Baseline to Week 4 in C-peptide Levels
ng/mLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 4 in C-peptide Levels0.002 ± 0.0705-0.032 ± 0.07270.076 ± 0.0734-0.246 ± 0.0730-0.248 ± 0.0714-0.238 ± 0.0720-0.232 ± 0.0721-0.259 ± 0.0718-0.268 ± 0.0705-0.393 ± 0.0714-0.252 ± 0.0734-0.337 ± 0.0738
SecondaryChange From Baseline to Week 8 in C-peptide Levels

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline C-peptide as continuous covariates.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · ng/mL
Change From Baseline to Week 8 in C-peptide Levels
ng/mLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 8 in C-peptide Levels-0.044 ± 0.07980.114 ± 0.08070.108 ± 0.0801-0.221 ± 0.0798-0.315 ± 0.0798-0.261 ± 0.0801-0.380 ± 0.0814-0.365 ± 0.0802-0.207 ± 0.0797-0.467 ± 0.0798-0.300 ± 0.0814-0.464 ± 0.0798
SecondaryChange From Baseline to Week 12 in C-peptide Levels

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline C-peptide as continuous covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · ng/mL
Change From Baseline to Week 12 in C-peptide Levels
ng/mLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 12 in C-peptide Levels-0.055 ± 0.13380.083 ± 0.13600.140 ± 0.13490.116 ± 0.1344-0.155 ± 0.1344-0.215 ± 0.1338-0.439 ± 0.1372-0.212 ± 0.1345-0.326 ± 0.1343-0.483 ± 0.1344-0.381 ± 0.1360-0.464 ± 0.1339
SecondaryChange From Baseline to Week 16 in C-peptide Levels

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline C-peptide as continuous covariates.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · ng/mL
Change From Baseline to Week 16 in C-peptide Levels
ng/mLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 16 in C-peptide Levels-0.076 ± 0.07830.032 ± 0.07960.101 ± 0.0789-0.242 ± 0.0786-0.282 ± 0.0780-0.184 ± 0.0783-0.410 ± 0.0796-0.318 ± 0.0783-0.306 ± 0.0786-0.404 ± 0.0786-0.431 ± 0.0789-0.510 ± 0.0783
SecondaryChange From Baseline to Week 20 in C-peptide Levels

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline C-peptide as continuous covariates.

Time frame:
Baseline and Week 20
Reported as:
Least squares mean · ng/mL
Change From Baseline to Week 20 in C-peptide Levels
ng/mLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 20 in C-peptide Levels-0.046 ± 0.07990.114 ± 0.08120.019 ± 0.0805-0.193 ± 0.0802-0.377 ± 0.0792-0.184 ± 0.0795-0.380 ± 0.0812-0.343 ± 0.0799-0.266 ± 0.0802-0.506 ± 0.0802-0.329 ± 0.0805-0.430 ± 0.0799
SecondaryChange From Baseline to Week 26 in C-peptide Levels

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline C-peptide as continuous covariates.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · ng/mL
Change From Baseline to Week 26 in C-peptide Levels
ng/mLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 26 in C-peptide Levels-0.011 ± 0.07930.000 ± 0.08020.059 ± 0.0799-0.239 ± 0.0792-0.380 ± 0.0783-0.204 ± 0.0789-0.353 ± 0.0805-0.235 ± 0.0790-0.300 ± 0.0795-0.429 ± 0.0793-0.421 ± 0.0796-0.474 ± 0.0793
SecondaryChange From Baseline in Total Cholesterol Over Time (Grouped Analysis)

Change from Baseline in total cholesterol was assessed at Weeks 4, 8, 12, 16, 20 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline total cholesterol as continuous covariates.

Time frame:
Baseline and Weeks 4, 8, 12, 16, 20 and 26.
Reported as:
Least squares mean · mg/dL
Change From Baseline in Total Cholesterol Over Time (Grouped Analysis)
mg/dLPioglitazone AloneAlogliptin 12.5 + PioglitazoneAlogliptin 25 + Pioglitazone
Week 4 (n=345, 354, 348)1.6 ± 1.41-4.3 ± 1.39-6.5 ± 1.40
Week 8 (n=374, 380, 376)4.8 ± 1.42-1.8 ± 1.41-3.3 ± 1.42
Week 12 (n=374, 380, 376)6.6 ± 1.471.3 ± 1.46-1.7 ± 1.46
Week 16 (n=374, 380, 376)6.5 ± 1.521.2 ± 1.510.1 ± 1.51
Week 20 (n=374, 380, 376)5.9 ± 1.563.0 ± 1.551.5 ± 1.56
Week 26 (n=374, 380, 376)8.0 ± 1.634.4 ± 1.613.9 ± 1.62
SecondaryChange From Baseline to Week 4 in Total Cholesterol Levels

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline total cholesterol as continuous covariates.

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 4 in Total Cholesterol Levels
mg/dLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 4 in Total Cholesterol Levels1.3 ± 2.40-3.8 ± 2.47-3.7 ± 2.482.1 ± 2.47-2.3 ± 2.42-10.2 ± 2.413.7 ± 2.42-7.2 ± 2.38-2.7 ± 2.41-1.2 ± 2.43-3.6 ± 2.43-6.7 ± 2.47
SecondaryChange From Baseline to Week 8 in Total Cholesterol Levels

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline total cholesterol as continuous covariates.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 8 in Total Cholesterol Levels
mg/dLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 8 in Total Cholesterol Levels10.9 ± 2.46-1.4 ± 2.50-0.3 ± 2.487.3 ± 2.46-2.3 ± 2.43-4.1 ± 2.446.6 ± 2.480.1 ± 2.450.3 ± 2.470.3 ± 2.45-3.1 ± 2.46-6.2 ± 2.46
SecondaryChange From Baseline to Week 12 in Total Cholesterol Levels

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline total cholesterol as continuous covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 12 in Total Cholesterol Levels
mg/dLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 12 in Total Cholesterol Levels7.8 ± 2.540.4 ± 2.570.1 ± 2.568.7 ± 2.541.9 ± 2.51-0.2 ± 2.527.3 ± 2.560.3 ± 2.52-1.0 ± 2.553.7 ± 2.531.7 ± 2.54-3.9 ± 2.54
SecondaryChange From Baseline to Week 16 in Total Cholesterol Levels

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline total cholesterol as continuous covariates.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 16 in Total Cholesterol Levels
mg/dLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 16 in Total Cholesterol Levels5.0 ± 2.62-0.5 ± 2.66-2.9 ± 2.657.2 ± 2.62-0.4 ± 2.593.2 ± 2.6010.0 ± 2.650.9 ± 2.61-1.2 ± 2.632.3 ± 2.612.9 ± 2.62-1.8 ± 2.62
SecondaryChange From Baseline to Week 20 in Total Cholesterol Levels

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline total cholesterol as continuous covariates.

Time frame:
Baseline and Week 20
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 20 in Total Cholesterol Levels
mg/dLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 20 in Total Cholesterol Levels6.7 ± 2.701.8 ± 2.74-1.9 ± 2.736.3 ± 2.704.0 ± 2.671.4 ± 2.687.0 ± 2.731.1 ± 2.683.4 ± 2.714.6 ± 2.694.0 ± 2.70-0.3 ± 2.70
SecondaryChange From Baseline to Week 26 in Total Cholesterol Levels

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline total cholesterol as continuous covariates.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 26 in Total Cholesterol Levels
mg/dLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 26 in Total Cholesterol Levels4.4 ± 2.822.2 ± 2.850.9 ± 2.845.8 ± 2.814.3 ± 2.783.5 ± 2.798.8 ± 2.842.8 ± 2.803.2 ± 2.839.5 ± 2.806.0 ± 2.815.1 ± 2.81
SecondaryChange From Baseline in Low-Density Lipoprotein Cholesterol Over Time (Grouped Analysis)

Change from Baseline in low-density lipoprotein cholesterol (LDL-C) was assessed at Weeks 4, 8, 12, 16, 20 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline LDL cholesterol as continuous covariates.

Time frame:
Baseline and Weeks 4, 8, 12, 16, 20 and 26.
Reported as:
Least squares mean · mg/dL
Change From Baseline in Low-Density Lipoprotein Cholesterol Over Time (Grouped Analysis)
mg/dLPioglitazone AloneAlogliptin 12.5 + PioglitazoneAlogliptin 25 + Pioglitazone
Week 4 (n=330, 336, 338)3.1 ± 1.23-0.5 ± 1.22-1.9 ± 1.22
Week 8 (n=365, 365, 365)5.9 ± 1.281.3 ± 1.280.1 ± 1.28
Week 12 (n=365, 367, 366)6.9 ± 1.293.3 ± 1.291.5 ± 1.29
Week 16 (n=365, 368, 366)6.1 ± 1.293.3 ± 1.292.4 ± 1.29
Week 20 (n=365, 368, 366)6.9 ± 1.374.2 ± 1.363.0 ± 1.37
Week 26 (n=365, 368, 366)7.4 ± 1.395.2 ± 1.395.6 ± 1.39
SecondaryChange From Baseline to Week 4 in Low-Density Lipoprotein Cholesterol

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline LDL cholesterol as continuous covariates.

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 4 in Low-Density Lipoprotein Cholesterol
mg/dLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 4 in Low-Density Lipoprotein Cholesterol2.1 ± 2.11-2.4 ± 2.221.4 ± 2.192.6 ± 2.161.6 ± 2.12-2.7 ± 2.113.2 ± 2.12-2.8 ± 2.090.4 ± 2.103.4 ± 2.13-0.3 ± 2.15-3.4 ± 2.13
SecondaryChange From Baseline to Week 8 in Low-Density Lipoprotein Cholesterol

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline LDL cholesterol as continuous covariates.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 8 in Low-Density Lipoprotein Cholesterol
mg/dLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 8 in Low-Density Lipoprotein Cholesterol9.4 ± 2.242.1 ± 2.303.4 ± 2.247.3 ± 2.21-0.4 ± 2.211.0 ± 2.215.4 ± 2.242.4 ± 2.212.7 ± 2.244.8 ± 2.212.0 ± 2.24-3.2 ± 2.20
SecondaryChange From Baseline to Week 12 in Low-Density Lipoprotein Cholesterol

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline LDL cholesterol as continuous covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 12 in Low-Density Lipoprotein Cholesterol
mg/dLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 12 in Low-Density Lipoprotein Cholesterol6.5 ± 2.261.9 ± 2.303.7 ± 2.268.9 ± 2.243.3 ± 2.213.8 ± 2.246.1 ± 2.261.9 ± 2.230.9 ± 2.255.7 ± 2.234.9 ± 2.26-0.3 ± 2.22
SecondaryChange From Baseline to Week 16 in Low-Density Lipoprotein Cholesterol

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline LDL cholesterol as continuous covariates.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 16 in Low-Density Lipoprotein Cholesterol
mg/dLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 16 in Low-Density Lipoprotein Cholesterol4.2 ± 2.251.3 ± 2.290.9 ± 2.267.1 ± 2.232.9 ± 2.214.6 ± 2.237.1 ± 2.252.1 ± 2.230.8 ± 2.254.1 ± 2.224.9 ± 2.251.8 ± 2.21
SecondaryChange From Baseline to Week 20 in Low-Density Lipoprotein Cholesterol

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline LDL cholesterol as continuous covariates.

Time frame:
Baseline and Week 20
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 20 in Low-Density Lipoprotein Cholesterol
mg/dLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 20 in Low-Density Lipoprotein Cholesterol6.9 ± 2.392.9 ± 2.431.9 ± 2.407.7 ± 2.374.3 ± 2.343.0 ± 2.376.6 ± 2.392.3 ± 2.364.1 ± 2.396.3 ± 2.366.1 ± 2.391.9 ± 2.35
SecondaryChange From Baseline to Week 26 in Low-Density Lipoprotein Cholesterol

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline LDL cholesterol as continuous covariates.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 26 in Low-Density Lipoprotein Cholesterol
mg/dLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 26 in Low-Density Lipoprotein Cholesterol3.6 ± 2.432.8 ± 2.473.6 ± 2.447.9 ± 2.413.7 ± 2.386.1 ± 2.416.2 ± 2.432.9 ± 2.403.0 ± 2.438.1 ± 2.409.1 ± 2.437.7 ± 2.39
SecondaryChange From Baseline in High-Density Lipoprotein Cholesterol Over Time (Grouped Analysis)

Change from Baseline in high-density lipoprotein cholesterol (HDL-C) was assessed at Weeks 4, 8, 12, 16, 20 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HDL cholesterol as continuous covariates.

Time frame:
Baseline and Weeks 4, 8, 12, 16, 20 and 26.
Reported as:
Least squares mean · mg/dL
Change From Baseline in High-Density Lipoprotein Cholesterol Over Time (Grouped Analysis)
mg/dLPioglitazone AloneAlogliptin 12.5 + PioglitazoneAlogliptin 25 + Pioglitazone
Week 4 (n=345, 353, 348)3.0 ± 0.332.7 ± 0.333.4 ± 0.33
Week 8 (n=374, 380, 376)4.0 ± 0.354.1 ± 0.344.6 ± 0.35
Week 12 (n=374, 380, 376)5.4 ± 0.375.3 ± 0.375.1 ± 0.37
Week 16 (n=374, 380, 376)5.2 ± 0.395.2 ± 0.385.0 ± 0.38
Week 20 (n=374, 380, 376)5.2 ± 0.405.7 ± 0.405.2 ± 0.40
Week 26 (n=374, 380, 376)5.1 ± 0.415.5 ± 0.415.0 ± 0.41
SecondaryChange From Baseline to Week 4 in High-Density Lipoprotein Cholesterol

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HDL cholesterol as continuous covariates.

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 4 in High-Density Lipoprotein Cholesterol
mg/dLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 4 in High-Density Lipoprotein Cholesterol-0.4 ± 0.57-0.6 ± 0.59-0.5 ± 0.592.5 ± 0.591.6 ± 0.581.6 ± 0.573.2 ± 0.572.3 ± 0.563.5 ± 0.573.3 ± 0.584.2 ± 0.585.1 ± 0.59
SecondaryChange From Baseline to Week 8 in High-Density Lipoprotein Cholesterol

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HDL cholesterol as continuous covariates.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 8 in High-Density Lipoprotein Cholesterol
mg/dLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 8 in High-Density Lipoprotein Cholesterol-0.5 ± 0.60-0.1 ± 0.610.6 ± 0.612.8 ± 0.602.3 ± 0.592.9 ± 0.604.8 ± 0.614.2 ± 0.604.6 ± 0.604.5 ± 0.605.7 ± 0.606.3 ± 0.60
SecondaryChange From Baseline to Week 12 in High-Density Lipoprotein Cholesterol

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HDL cholesterol as continuous covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 12 in High-Density Lipoprotein Cholesterol
mg/dLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 12 in High-Density Lipoprotein Cholesterol-0.2 ± 0.640.0 ± 0.650.3 ± 0.643.8 ± 0.643.7 ± 0.633.7 ± 0.636.3 ± 0.645.8 ± 0.635.3 ± 0.646.1 ± 0.636.3 ± 0.646.4 ± 0.64
SecondaryChange From Baseline to Week 16 in High-Density Lipoprotein Cholesterol

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HDL cholesterol as continuous covariates.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 16 in High-Density Lipoprotein Cholesterol
mg/dLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 16 in High-Density Lipoprotein Cholesterol-0.3 ± 0.670.4 ± 0.680.7 ± 0.673.9 ± 0.674.2 ± 0.664.0 ± 0.665.7 ± 0.675.5 ± 0.664.3 ± 0.675.9 ± 0.666.1 ± 0.676.7 ± 0.67
SecondaryChange From Baseline to Week 20 in High-Density Lipoprotein Cholesterol

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HDL cholesterol as continuous covariates.

Time frame:
Baseline and Week 20
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 20 in High-Density Lipoprotein Cholesterol
mg/dLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 20 in High-Density Lipoprotein Cholesterol0.6 ± 0.700.9 ± 0.710.5 ± 0.703.8 ± 0.704.3 ± 0.693.9 ± 0.695.9 ± 0.705.7 ± 0.695.3 ± 0.705.9 ± 0.707.1 ± 0.706.5 ± 0.70
SecondaryChange From Baseline to Week 26 in High-Density Lipoprotein Cholesterol

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HDL cholesterol as continuous covariates.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 26 in High-Density Lipoprotein Cholesterol
mg/dLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 26 in High-Density Lipoprotein Cholesterol0.5 ± 0.710.6 ± 0.721.3 ± 0.713.8 ± 0.714.2 ± 0.704.1 ± 0.705.5 ± 0.716.0 ± 0.705.0 ± 0.716.1 ± 0.706.2 ± 0.716.0 ± 0.71
SecondaryChange From Baseline in Triglycerides Over Time (Grouped Analysis)

Change from Baseline in triglycerides was assessed at Weeks 4, 8, 12, 16, 20 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline triglycerides as continuous covariates.

Time frame:
Baseline and Weeks 4, 8, 12, 16, 20 and 26.
Reported as:
Least squares mean · mg/dL
Change From Baseline in Triglycerides Over Time (Grouped Analysis)
mg/dLPioglitazone AloneAlogliptin 12.5 + PioglitazoneAlogliptin 25 + Pioglitazone
Week 4 (n=345, 354, 348)-31.5 ± 4.07-38.9 ± 4.02-48.0 ± 4.06
Week 8 (n=374, 380, 376)-34.7 ± 4.37-44.4 ± 4.34-47.9 ± 4.36
Week 12 (n=374, 380, 376)-34.5 ± 4.25-47.5 ± 4.21-49.4 ± 4.24
Week 16 (n=374, 380, 376)-29.4 ± 4.43-49.3 ± 4.39-46.3 ± 4.42
Week 20 (n=374, 380, 376)-34.9 ± 4.30-43.6 ± 4.27-42.7 ± 4.29
Week 26 (n=374, 380, 376)-29.6 ± 4.42-41.4 ± 4.39-40.7 ± 4.41
SecondaryChange From Baseline to Week 4 in Triglyceride Levels

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline triglycerides as continuous covariates.

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 4 in Triglyceride Levels
mg/dLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 4 in Triglyceride Levels-2.4 ± 6.93-2.2 ± 7.15-25.0 ± 7.18-21.5 ± 7.14-35.8 ± 6.99-51.1 ± 6.96-26.7 ± 6.99-42.2 ± 6.88-44.4 ± 6.96-47.1 ± 7.02-39.2 ± 7.03-49.1 ± 7.15
SecondaryChange From Baseline to Week 8 in Triglyceride Levels

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline triglycerides as continuous covariates.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 8 in Triglyceride Levels
mg/dLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 8 in Triglyceride Levels26.3 ± 7.56-16.4 ± 7.69-23.0 ± 7.62-20.5 ± 7.56-30.1 ± 7.47-46.4 ± 7.50-30.3 ± 7.62-43.1 ± 7.51-44.5 ± 7.60-53.1 ± 7.53-60.1 ± 7.57-52.7 ± 7.56
SecondaryChange From Baseline to Week 12 in Triglyceride Levels

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline triglycerides as continuous covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 12 in Triglyceride Levels
mg/dLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 12 in Triglyceride Levels18.9 ± 7.35-4.3 ± 7.44-18.1 ± 7.41-24.1 ± 7.34-37.4 ± 7.26-44.0 ± 7.29-37.4 ± 7.40-47.9 ± 7.29-46.8 ± 7.38-42.1 ± 7.31-57.1 ± 7.35-57.4 ± 7.35
SecondaryChange From Baseline to Week 16 in Triglyceride Levels

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline triglycerides as continuous covariates.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 16 in Triglyceride Levels
mg/dLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 16 in Triglyceride Levels10.6 ± 7.66-7.5 ± 7.75-26.8 ± 7.72-10.5 ± 7.66-53.0 ± 7.57-33.8 ± 7.60-28.2 ± 7.72-44.2 ± 7.60-45.9 ± 7.69-49.4 ± 7.63-50.7 ± 7.66-59.1 ± 7.66
SecondaryChange From Baseline to Week 20 in Triglyceride Levels

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline triglycerides as continuous covariates.

Time frame:
Baseline and Week 20
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 20 in Triglyceride Levels
mg/dLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 20 in Triglyceride Levels5.7 ± 7.44-7.0 ± 7.53-23.7 ± 7.50-18.0 ± 7.44-41.2 ± 7.35-34.6 ± 7.38-37.5 ± 7.50-43.1 ± 7.39-42.4 ± 7.47-49.3 ± 7.41-46.4 ± 7.44-51.2 ± 7.44
SecondaryChange From Baseline to Week 26 in Triglyceride Levels

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline triglycerides as continuous covariates.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 26 in Triglyceride Levels
mg/dLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 26 in Triglyceride Levels3.7 ± 7.65-1.1 ± 7.74-15.2 ± 7.71-29.5 ± 7.65-37.7 ± 7.56-38.5 ± 7.59-27.0 ± 7.71-37.3 ± 7.59-33.5 ± 7.68-32.4 ± 7.62-49.3 ± 7.65-50.1 ± 7.65
SecondaryChange From Baseline in Free Fatty Acids Over Time (Grouped Analysis)

Change from Baseline in free fatty acids (FFA) was assessed at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline free fatty acid as continuous covariates.

Time frame:
Baseline and Weeks 12 and 26.
Reported as:
Least squares mean · mmol/L
Change From Baseline in Free Fatty Acids Over Time (Grouped Analysis)
mmol/LPioglitazone AloneAlogliptin 12.5 + PioglitazoneAlogliptin 25 + Pioglitazone
Week 12 (n=339, 356, 352)-0.0707 ± 0.01483-0.1306 ± 0.01447-0.1273 ± 0.01455
Week 26 (n=353, 368, 363)-0.0676 ± 0.01050-0.0945 ± 0.01029-0.1144 ± 0.01036
SecondaryChange From Baseline to Week 12 in Free Fatty Acids

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline free fatty acid as continuous covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · mmol/L
Change From Baseline to Week 12 in Free Fatty Acids
mmol/LPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 12 in Free Fatty Acids0.0067 ± 0.02493-0.0149 ± 0.02535-0.0769 ± 0.02535-0.0879 ± 0.02547-0.1305 ± 0.02502-0.1291 ± 0.02512-0.0395 ± 0.02592-0.1167 ± 0.02515-0.1126 ± 0.02534-0.0848 ± 0.02567-0.1447 ± 0.02503-0.1401 ± 0.02514
SecondaryChange From Baseline to Week 26 in Free Fatty Acids

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline free fatty acid as continuous covariates.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · mmol/L
Change From Baseline to Week 26 in Free Fatty Acids
mmol/LPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 26 in Free Fatty Acids-0.0387 ± 0.01788-0.0427 ± 0.01802-0.0386 ± 0.01787-0.0561 ± 0.01825-0.0752 ± 0.01772-0.0972 ± 0.01793-0.0737 ± 0.01817-0.0956 ± 0.01788-0.1232 ± 0.01801-0.0730 ± 0.01816-0.1125 ± 0.01787-0.1228 ± 0.01787
SecondaryChange From Baseline in Plasminogen Activator Inhibitor-1 Over Time (Grouped Analysis)

Change from Baseline in plasminogen activator inhibitor-1 (PAI-1) was assessed at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline PAI-1 as continuous covariates.

Time frame:
Baseline and Weeks 12 and 26.
Reported as:
Least squares mean · ng/mL
Change From Baseline in Plasminogen Activator Inhibitor-1 Over Time (Grouped Analysis)
ng/mLPioglitazone AloneAlogliptin 12.5 + PioglitazoneAlogliptin 25 + Pioglitazone
Week 12 (n=311, 333, 328)-4.14 ± 1.970-8.76 ± 1.900-8.57 ± 1.914
Week 26 (n=341, 354, 348)-4.56 ± 2.049-2.69 ± 2.010-9.25 ± 2.027
SecondaryChange From Baseline to Week 12 in Plasminogen Activator Inhibitor-1

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline PAI-1 as continuous covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · ng/mL
Change From Baseline to Week 12 in Plasminogen Activator Inhibitor-1
ng/mLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 12 in Plasminogen Activator Inhibitor-1-4.55 ± 3.3673.54 ± 3.350-1.80 ± 3.353-5.32 ± 3.340-6.28 ± 3.260-10.94 ± 3.320-8.53 ± 3.353-10.47 ± 3.336-1.71 ± 3.3211.85 ± 3.539-9.13 ± 3.277-12.63 ± 3.306
SecondaryChange From Baseline to Week 26 in Plasminogen Activator Inhibitor-1

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline PAI-1 as continuous covariates.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · ng/mL
Change From Baseline to Week 26 in Plasminogen Activator Inhibitor-1
ng/mLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 26 in Plasminogen Activator Inhibitor-1-3.00 ± 3.5260.57 ± 3.540-3.29 ± 3.481-5.43 ± 3.529-4.75 ± 3.465-9.62 ± 3.510-5.24 ± 3.4951.89 ± 3.511-6.66 ± 3.525-3.02 ± 3.622-5.22 ± 3.466-11.48 ± 3.496
SecondaryChange From Baseline in High-sensitivity C-Reactive Protein Over Time (Grouped Analysis)

Change from Baseline in high-sensitivity C-Reactive Protein (hsCRP) was assessed at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline hsCRP as continuous covariates.

Time frame:
Baseline and Weeks 12 and 26.
Reported as:
Least squares mean · mg/L
Change From Baseline in High-sensitivity C-Reactive Protein Over Time (Grouped Analysis)
mg/LPioglitazone AloneAlogliptin 12.5 + PioglitazoneAlogliptin 25 + Pioglitazone
Week 12 (n=346, 356, 355)-2.0274 ± 0.32717-2.4653 ± 0.32225-1.9208 ± 0.32253
Week 26 (n=359, 369, 363)-0.8889 ± 0.46384-1.7716 ± 0.45715-0.9977 ± 0.46059
SecondaryChange From Baseline to Week 12 in High-sensitivity C-Reactive Protein

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline hsCRP as continuous covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · mg/L
Change From Baseline to Week 12 in High-sensitivity C-Reactive Protein
mg/LPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 12 in High-sensitivity C-Reactive Protein-1.1053 ± 0.55528-1.0730 ± 0.569420.3516 ± 0.55954-0.9166 ± 0.56902-2.2362 ± 0.55706-2.4217 ± 0.55929-2.7023 ± 0.55971-2.2143 ± 0.55757-1.0006 ± 0.56412-2.4212 ± 0.57137-2.9032 ± 0.55979-2.2978 ± 0.55243
SecondaryChange From Baseline to Week 26 in High-sensitivity C-Reactive Protein

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline hsCRP as continuous covariates.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · mg/L
Change From Baseline to Week 26 in High-sensitivity C-Reactive Protein
mg/LPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 26 in High-sensitivity C-Reactive Protein-0.0550 ± 0.79868-0.6606 ± 0.801450.2618 ± 0.794880.2375 ± 0.80439-1.2490 ± 0.78817-0.9438 ± 0.79442-1.0480 ± 0.79805-1.1725 ± 0.792060.1697 ± 0.80434-1.8562 ± 0.80771-2.8933 ± 0.79515-2.2191 ± 0.79450
SecondaryChange From Baseline in Adiponectin Over Time (Grouped Analysis)

Change from Baseline in adiponectin was assessed at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline adiponectin as continuous covariates.

Time frame:
Baseline and Weeks 12 and 26.
Reported as:
Least squares mean · μg/mL
Change From Baseline in Adiponectin Over Time (Grouped Analysis)
μg/mLPioglitazone AloneAlogliptin 12.5 + PioglitazoneAlogliptin 25 + Pioglitazone
Week 12 (n=339, 357, 348)6.03 ± 0.3536.51 ± 0.3446.51 ± 0.348
Week 26 (n=356, 369, 361)5.98 ± 0.3966.43 ± 0.3886.46 ± 0.393
SecondaryChange From Baseline to Week 12 in Adiponectin

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline adiponectin as continuous covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · μg/mL
Change From Baseline to Week 12 in Adiponectin
μg/mLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 12 in Adiponectin0.02 ± 0.5930.44 ± 0.6090.22 ± 0.6063.54 ± 0.6043.78 ± 0.5912.91 ± 0.6016.07 ± 0.6176.31 ± 0.5997.13 ± 0.6098.47 ± 0.6149.42 ± 0.5989.46 ± 0.601
SecondaryChange From Baseline to Week 26 in Adiponectin

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline adiponectin as continuous covariates.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · μg/mL
Change From Baseline to Week 26 in Adiponectin
μg/mLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 26 in Adiponectin0.43 ± 0.6760.48 ± 0.6810.26 ± 0.6783.30 ± 0.6854.80 ± 0.6642.93 ± 0.6785.90 ± 0.6876.30 ± 0.6766.87 ± 0.6848.75 ± 0.6848.18 ± 0.6789.59 ± 0.678
SecondaryChange From Baseline in Body Weight Over Time (Grouped Analysis)

Change from Baseline in body weight was assessed at Weeks 8, 12, 20 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline weight as continuous covariates.

Time frame:
Baseline and Weeks 8, 12, 20 and 26.
Reported as:
Least squares mean · kg
Change From Baseline in Body Weight Over Time (Grouped Analysis)
kgPioglitazone AloneAlogliptin 12.5 + PioglitazoneAlogliptin 25 + Pioglitazone
Week 8 (n=361, 372, 367)0.45 ± 0.1030.34 ± 0.1010.63 ± 0.102
Week 12 (n=368, 374, 373)0.56 ± 0.1250.57 ± 0.1240.82 ± 0.124
Week 20 (n=368, 374, 373)1.21 ± 0.1521.45 ± 0.1511.46 ± 0.151
Week 26 (n=368, 374, 373)1.49 ± 0.1681.81 ± 0.1671.87 ± 0.167
SecondaryChange From Baseline to Week 8 in Body Weight

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline weight as continuous covariates.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · kg
Change From Baseline to Week 8 in Body Weight
kgPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 8 in Body Weight-0.13 ± 0.176-0.05 ± 0.179-0.45 ± 0.1780.32 ± 0.1770.09 ± 0.1740.22 ± 0.1760.57 ± 0.1770.49 ± 0.1740.74 ± 0.1770.46 ± 0.1790.43 ± 0.1770.93 ± 0.175
SecondaryChange From Baseline to Week 12 in Body Weight

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline weight as continuous covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · kg
Change From Baseline to Week 12 in Body Weight
kgPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 12 in Body Weight-0.46 ± 0.216-0.14 ± 0.217-0.56 ± 0.2160.39 ± 0.2170.22 ± 0.2130.39 ± 0.2150.75 ± 0.2170.60 ± 0.2150.98 ± 0.2160.55 ± 0.2160.88 ± 0.2171.08 ± 0.214
SecondaryChange From Baseline to Week 20 in Body Weight

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline weight as continuous covariates.

Time frame:
Baseline and Week 20
Reported as:
Least squares mean · kg
Change From Baseline to Week 20 in Body Weight
kgPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 20 in Body Weight-0.55 ± 0.263-0.08 ± 0.264-0.48 ± 0.2630.76 ± 0.2640.96 ± 0.2590.85 ± 0.2621.51 ± 0.2641.45 ± 0.2611.76 ± 0.2631.35 ± 0.2621.93 ± 0.2641.76 ± 0.260
SecondaryChange From Baseline to Week 26 in Body Weight

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline weight as continuous covariates.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · kg
Change From Baseline to Week 26 in Body Weight
kgPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 26 in Body Weight-0.66 ± 0.291-0.02 ± 0.292-0.67 ± 0.2910.94 ± 0.2921.25 ± 0.2871.27 ± 0.2901.88 ± 0.2921.89 ± 0.2892.10 ± 0.2911.65 ± 0.2902.30 ± 0.2922.25 ± 0.288
SecondaryChange From Baseline in Calculated Homeostatic Model Assessment Insulin Resistance (HOMA IR) (Grouped Analysis)

HOMA IR measures insulin resistance based on fasting glucose and insulin measurements: HOMA IR = fasting plasma insulin (µIU/mL) \* fasting plasma glucose (mmol/L) / 22.5. A higher number indicates a greater insulin resistance. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least Squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and HOMA-IR as continuous covariates.

Time frame:
Baseline and Weeks 12 and 26.
Reported as:
Least squares mean · insulin resistance
Change From Baseline in Calculated Homeostatic Model Assessment Insulin Resistance (HOMA IR) (Grouped Analysis)
insulin resistancePioglitazone AloneAlogliptin 12.5 + PioglitazoneAlogliptin 25 + Pioglitazone
Week 12 (n=347, 344, 351)-1.832 ± 0.3122-1.966 ± 0.3136-2.572 ± 0.3104
Week 26 (n=348, 346, 352)-1.571 ± 0.3501-2.209 ± 0.3512-1.711 ± 0.3481
SecondaryChange From Baseline to Week 12 in Calculated HOMA Insulin Resistance

The Homeostasis Model Assessment of insulin resistance (HOMA IR) measures insulin resistance based on fasting glucose and insulin measurements: HOMA IR = fasting plasma insulin (µIU/mL) \* fasting plasma glucose (mmol/L) / 22.5. A higher number indicates a greater degree of insulin resistance. Least Squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and HOMA-IR as continuous covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · insulin resistance
Change From Baseline to Week 12 in Calculated HOMA Insulin Resistance
insulin resistancePlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 12 in Calculated HOMA Insulin Resistance0.337 ± 0.53330.063 ± 0.53750.041 ± 0.5270-1.012 ± 0.5330-1.819 ± 0.5376-2.305 ± 0.5352-2.278 ± 0.5446-1.457 ± 0.5473-2.665 ± 0.5400-2.202 ± 0.5447-2.615 ± 0.5446-2.742 ± 0.5377
SecondaryChange From Baseline to Week 26 in Calculated HOMA Insulin Resistance

The Homeostasis Model Assessment of insulin resistance (HOMA IR) measures insulin resistance based on fasting glucose and insulin measurements: HOMA IR = fasting plasma insulin (µIU/mL) \* fasting plasma glucose (mmol/L) / 22.5. A higher number indicates a greater degree of insulin resistance. Least Squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and HOMA-IR as continuous covariates.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · insulin resistance
Change From Baseline to Week 26 in Calculated HOMA Insulin Resistance
insulin resistancePlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 26 in Calculated HOMA Insulin Resistance0.464 ± 0.59880.311 ± 0.6036-0.179 ± 0.5918-0.864 ± 0.5985-2.300 ± 0.5986-0.223 ± 0.5985-2.061 ± 0.6089-1.871 ± 0.6147-2.056 ± 0.6064-1.789 ± 0.6117-2.456 ± 0.6116-2.854 ± 0.6038
SecondaryChange From Baseline in Homeostatic Model Assessment Beta Cell Function (Grouped Analysis)

The homeostatic model assessment estimates steady state beta cell function as a percentage of a normal reference population (%B). HOMA %B = 20 \* insulin (µIU/mL) / fasting plasma glucose (mmol/L) - 3.5. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HOMA beta cell function as continuous covariates.

Time frame:
Baseline and Weeks 12 and 26
Reported as:
Least squares mean · percentage beta cell function
Change From Baseline in Homeostatic Model Assessment Beta Cell Function (Grouped Analysis)
percentage beta cell functionPioglitazone AloneAlogliptin 12.5 + PioglitazoneAlogliptin 25 + Pioglitazone
Week 12 (n=347, 344, 350)2.591 ± 3.789223.799 ± 3.801719.477 ± 3.7685
Week 26 (n=348, 346, 351)5.060 ± 3.046018.173 ± 3.052222.182 ± 3.0297
SecondaryChange From Baseline to Week 12 in Calculated HOMA Beta-cell Function

The Homeostasis Model Assessment (HOMA) estimates steady state beta cell function (%B) as a percentage of a normal reference population. HOMA %B = 20 \* insulin (µIU/mL) / fasting plasma glucose (mmol/L) - 3.5. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HOMA beta cell function as continuous covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percentage beta cell function
Change From Baseline to Week 12 in Calculated HOMA Beta-cell Function
percentage beta cell functionPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 12 in Calculated HOMA Beta-cell Function-3.027 ± 6.491516.304 ± 6.516522.996 ± 6.38542.565 ± 6.461430.346 ± 6.515719.887 ± 6.49161.118 ± 6.603021.045 ± 6.635819.935 ± 6.54444.023 ± 6.624019.938 ± 6.602518.541 ± 6.5456
SecondaryChange From Baseline to Week 26 in Calculated HOMA Beta-cell Function

The Homeostasis Model Assessment (HOMA) estimates steady state beta cell function (%B) as a percentage of a normal reference population. HOMA %B = 20 \* insulin (µIU/mL) / fasting plasma glucose (mmol/L) - 3.5. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HOMA beta cell function as continuous covariates.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · percentage beta cell function
Change From Baseline to Week 26 in Calculated HOMA Beta-cell Function
percentage beta cell functionPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 26 in Calculated HOMA Beta-cell Function-0.924 ± 5.226011.812 ± 5.246217.814 ± 5.14072.770 ± 5.201810.977 ± 5.201019.320 ± 5.20448.983 ± 5.292122.474 ± 5.342323.475 ± 5.26873.427 ± 5.332721.068 ± 5.315423.752 ± 5.2696
SecondaryChange From Baseline in Apolipoprotein A1 Over Time (Grouped Analysis)

Change from Baseline in Apolipoprotein A1 was assessed at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein A1 as continuous covariates.

Time frame:
Baseline and Weeks 12 and 26.
Reported as:
Least squares mean · mg/dL
Change From Baseline in Apolipoprotein A1 Over Time (Grouped Analysis)
mg/dLPioglitazone AloneAlogliptin 12.5 + PioglitazoneAlogliptin 25 + Pioglitazone
Week 12 (n=339, 354, 346)1.4 ± 1.000.2 ± 0.980.3 ± 0.99
Week 26 (n=354, 367, 356)-1.6 ± 1.09-1.5 ± 1.08-2.8 ± 1.09
SecondaryChange From Baseline to Week 12 in Apolipoprotein A1

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein A1 as continuous covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 12 in Apolipoprotein A1
mg/dLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 12 in Apolipoprotein A1-1.9 ± 1.70-4.4 ± 1.73-3.0 ± 1.740.8 ± 1.73-1.3 ± 1.691.7 ± 1.723.5 ± 1.720.7 ± 1.690.4 ± 1.69-0.1 ± 1.741.1 ± 1.71-1.2 ± 1.72
SecondaryChange From Baseline to Week 26 in Apolipoprotein A1

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein A1 as continuous covariates.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 26 in Apolipoprotein A1
mg/dLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 26 in Apolipoprotein A1-4.9 ± 1.88-3.0 ± 1.90-4.2 ± 1.89-3.3 ± 1.90-3.5 ± 1.84-2.9 ± 1.91-0.2 ± 1.89-0.1 ± 1.86-3.2 ± 1.87-1.4 ± 1.89-1.0 ± 1.88-2.2 ± 1.89
SecondaryChange From Baseline in Apolipoprotein A2 Over Time (Grouped Analysis)

Change from Baseline in Apolipoprotein A2 was assessed at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein A2 as continuous covariates.

Time frame:
Baseline and Weeks 12 and 26
Reported as:
Least squares mean · mg/dL
Change From Baseline in Apolipoprotein A2 Over Time (Grouped Analysis)
mg/dLPioglitazone AloneAlogliptin 12.5 + PioglitazoneAlogliptin 25 + Pioglitazone
Week 12 (n=339, 354, 345)3.1 ± 0.262.5 ± 0.262.3 ± 0.26
Week 26 (n=354, 367, 355)2.4 ± 0.282.1 ± 0.271.8 ± 0.28
SecondaryChange From Baseline to Week 12 in Apolipoprotein A2

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein A2 as continuous covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 12 in Apolipoprotein A2
mg/dLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 12 in Apolipoprotein A20.4 ± 0.440.1 ± 0.450.4 ± 0.452.4 ± 0.451.4 ± 0.441.9 ± 0.453.7 ± 0.452.5 ± 0.441.8 ± 0.443.0 ± 0.453.7 ± 0.453.2 ± 0.45
SecondaryChange From Baseline to Week 26 in Apolipoprotein A2

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein A2 as continuous covariates.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 26 in Apolipoprotein A2
mg/dLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 26 in Apolipoprotein A20.1 ± 0.470.2 ± 0.480.4 ± 0.481.9 ± 0.481.2 ± 0.471.0 ± 0.482.7 ± 0.482.1 ± 0.471.6 ± 0.472.8 ± 0.483.1 ± 0.472.7 ± 0.48
SecondaryChange From Baseline in Apolipoprotein B Over Time (Grouped Analysis)

Change from Baseline in Apolipoprotein B was assessed at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein B as continuous covariates.

Time frame:
Baseline and Weeks 12 and 26
Reported as:
Least squares mean · mg/dL
Change From Baseline in Apolipoprotein B Over Time (Grouped Analysis)
mg/dLPioglitazone AloneAlogliptin 12.5 + PioglitazoneAlogliptin 25 + Pioglitazone
Week 12 (n=338, 354, 346)-3.0 ± 1.09-7.9 ± 1.06-10.0 ± 1.07
Week 26 (n=354, 367, 356)-2.8 ± 1.16-6.4 ± 1.14-6.4 ± 1.15
SecondaryChange From Baseline to Week 12 in Apolipoprotein B

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein B as continuous covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 12 in Apolipoprotein B
mg/dLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 12 in Apolipoprotein B5.0 ± 1.85-2.3 ± 1.87-3.6 ± 1.89-0.3 ± 1.88-7.2 ± 1.83-6.1 ± 1.87-2.1 ± 1.88-8.4 ± 1.83-12.2 ± 1.84-6.6 ± 1.90-8.0 ± 1.86-11.7 ± 1.87
SecondaryChange From Baseline to Week 26 in Apolipoprotein B

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein B as continuous covariates.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 26 in Apolipoprotein B
mg/dLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 26 in Apolipoprotein B0.6 ± 1.99-0.6 ± 2.00-3.7 ± 2.00-1.5 ± 2.01-6.0 ± 1.95-4.8 ± 2.02-3.2 ± 2.00-7.2 ± 1.97-8.8 ± 1.98-3.6 ± 2.00-6.1 ± 1.99-5.5 ± 2.00
SecondaryChange From Baseline in Apolipoprotein C-III Over Time (Grouped Analysis)

Change from Baseline in apolipoprotein C-III was assessed at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein C-III as continuous covariates.

Time frame:
Baseline and Weeks 12 and 26
Reported as:
Least squares mean · mg/dL
Change From Baseline in Apolipoprotein C-III Over Time (Grouped Analysis)
mg/dLPioglitazone AloneAlogliptin 12.5 + PioglitazoneAlogliptin 25 + Pioglitazone
Week 12 (n=337, 352, 345)-0.6 ± 0.17-1.2 ± 0.16-1.3 ± 0.17
Week 26 (n=353, 366, 355)-0.1 ± 0.19-0.6 ± 0.19-0.6 ± 0.19
SecondaryChange From Baseline to Week 12 in Apolipoprotein C-III

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein C-III as continuous covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 12 in Apolipoprotein C-III
mg/dLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 12 in Apolipoprotein C-III0.7 ± 0.28-0.4 ± 0.29-0.7 ± 0.29-0.3 ± 0.29-1.0 ± 0.28-1.4 ± 0.29-0.3 ± 0.29-1.0 ± 0.28-1.3 ± 0.28-1.1 ± 0.29-1.4 ± 0.29-1.2 ± 0.29
SecondaryChange From Baseline to Week 26 in Apolipoprotein C-III

Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein C-III as continuous covariates.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 26 in Apolipoprotein C-III
mg/dLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 26 in Apolipoprotein C-III0.4 ± 0.330.5 ± 0.33-0.7 ± 0.33-0.4 ± 0.33-0.6 ± 0.32-0.7 ± 0.330.2 ± 0.33-0.4 ± 0.32-0.6 ± 0.320.0 ± 0.33-0.7 ± 0.33-0.5 ± 0.33
SecondaryChange From Baseline in Nuclear Magnetic Resonance Lipid Fractionation Total Triglycerides Over Time (Grouped Analysis)

Nuclear Magnetic Resonance (NMR) lipid fractionation was used to assess the change from Baseline in total triglyceride levels at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR total triglycerides as continuous covariates.

Time frame:
Baseline and Weeks 12 and 26.
Reported as:
Least squares mean · mg/dL
Change From Baseline in Nuclear Magnetic Resonance Lipid Fractionation Total Triglycerides Over Time (Grouped Analysis)
mg/dLPioglitazone AloneAlogliptin 12.5 + PioglitazoneAlogliptin 25 + Pioglitazone
Week 12 (n=332, 345, 343)-19.6 ± 3.92-28.8 ± 3.85-31.5 ± 3.86
Week 26 (n=348, 359, 357)-11.5 ± 4.30-25.4 ± 4.23-22.9 ± 4.24
SecondaryChange From Baseline to Week 12 in NMR Lipid Fractionation Total Triglycerides

NMR lipid fractionation was used to assess the change from Baseline in total triglyceride levels at Week 12. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR total triglycerides as continuous covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 12 in NMR Lipid Fractionation Total Triglycerides
mg/dLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 12 in NMR Lipid Fractionation Total Triglycerides20.6 ± 6.56-4.9 ± 6.73-7.8 ± 6.70-12.9 ± 6.72-21.8 ± 6.70-27.2 ± 6.61-18.3 ± 6.82-29.8 ± 6.73-31.6 ± 6.82-27.9 ± 6.85-35.1 ± 6.59-36.0 ± 6.64
SecondaryChange From Baseline to Week 26 in NMR Lipid Fractionation Total Triglycerides

NMR lipid fractionation was used to assess the change from Baseline in total triglyceride levels at Week 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR total triglycerides as continuous covariates.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 26 in NMR Lipid Fractionation Total Triglycerides
mg/dLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 26 in NMR Lipid Fractionation Total Triglycerides12.4 ± 7.267.3 ± 7.42-6.8 ± 7.32-18.9 ± 7.44-20.4 ± 7.32-23.1 ± 7.32-6.9 ± 7.44-23.5 ± 7.38-19.7 ± 7.44-8.6 ± 7.44-32.1 ± 7.29-25.8 ± 7.29
SecondaryChange From Baseline in Very Low Density Lipoprotein (VLDL) / Chylomicron Particles Over Time (Grouped Analysis)

The change from Baseline in levels of total VLDL/chylomicron particles and large VLDL/chylomicron particles was assessed by NMR lipid fractionation at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR VLDL/chylomicron particles as continuous covariates.

Time frame:
Baseline and Weeks 12 and 26
Reported as:
Least squares mean · nmol/L
Change From Baseline in Very Low Density Lipoprotein (VLDL) / Chylomicron Particles Over Time (Grouped Analysis)
nmol/LPioglitazone AloneAlogliptin 12.5 + PioglitazoneAlogliptin 25 + Pioglitazone
Total Particles - Week 12 (n=332, 345, 343)-1.85 ± 1.803-6.40 ± 1.770-7.26 ± 1.775
Total Particles - Week 26 (n=348, 359, 357)-1.05 ± 1.999-1.87 ± 1.970-1.31 ± 1.975
Large Particles - Week 12 (n=332, 345, 343)-1.61 ± 0.289-2.20 ± 0.283-2.17 ± 0.284
Large Particles - Week 26 (n=348, 359, 357)-1.05 ± 0.342-2.25 ± 0.337-1.98 ± 0.337
SecondaryChange From Baseline to Week 12 in VLDL / Chylomicron Particles

The change from Baseline in levels of total VLDL/chylomicron particles and large VLDL/chylomicron particles was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR VLDL/chylomicron particles as continuous covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · nmol/L
Change From Baseline to Week 12 in VLDL / Chylomicron Particles
nmol/LPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Total Particles5.82 ± 3.013-1.59 ± 3.092-5.32 ± 3.0772.52 ± 3.089-3.46 ± 3.077-5.57 ± 3.0370.45 ± 3.135-7.82 ± 3.092-6.54 ± 3.132-8.58 ± 3.147-7.99 ± 3.027-9.76 ± 3.051
Large Particles1.12 ± 0.482-0.42 ± 0.495-0.27 ± 0.493-1.20 ± 0.495-1.63 ± 0.493-1.81 ± 0.486-1.69 ± 0.502-2.19 ± 0.495-2.29 ± 0.501-1.97 ± 0.504-2.81 ± 0.484-2.45 ± 0.489
SecondaryChange From Baseline to Week 26 in VLDL / Chylomicron Particles

The change from Baseline in levels of total VLDL/chylomicron particles and large VLDL/chylomicron particles was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR VLDL/chylomicron particles as continuous covariates.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · nmol/L
Change From Baseline to Week 26 in VLDL / Chylomicron Particles
nmol/LPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Total Particles2.80 ± 3.3790.59 ± 3.450-5.79 ± 3.405-2.99 ± 3.462-3.31 ± 3.405-5.15 ± 3.4053.68 ± 3.464-0.59 ± 3.436-0.35 ± 3.463-3.83 ± 3.463-1.70 ± 3.3941.56 ± 3.392
Large Particles1.31 ± 0.5770.94 ± 0.589-0.14 ± 0.582-1.56 ± 0.592-1.71 ± 0.582-1.80 ± 0.582-0.90 ± 0.592-2.24 ± 0.587-1.79 ± 0.592-0.67 ± 0.592-2.80 ± 0.580-2.36 ± 0.580
SecondaryChange From Baseline in VLDL / Chylomicron Triglycerides Over Time (Grouped Analysis)

The change from Baseline in levels of VLDL/chylomicron triglycerides was assessed by NMR lipid fractionation at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR VLDL/chylomicron triglycerides as continuous covariates.

Time frame:
Baseline and Weeks 12 and 26
Reported as:
Least squares mean · mg/dL
Change From Baseline in VLDL / Chylomicron Triglycerides Over Time (Grouped Analysis)
mg/dLPioglitazone AloneAlogliptin 12.5 + PioglitazoneAlogliptin 25 + Pioglitazone
Week 12 (n=332, 345, 343)-20.4 ± 3.90-28.5 ± 3.83-30.3 ± 3.84
Week 26 (n=348, 359, 357)-13.0 ± 4.28-25.4 ± 4.22-23.0 ± 4.23
SecondaryChange From Baseline to Week 12 in VLDL / Chylomicron Triglycerides

The change from Baseline in VLDL/chylomicron triglyceride levels was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR VLDL/chylomicron triglycerides as continuous covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 12 in VLDL / Chylomicron Triglycerides
mg/dLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 12 in VLDL / Chylomicron Triglycerides19.9 ± 6.51-3.5 ± 6.69-6.4 ± 6.65-14.2 ± 6.68-21.1 ± 6.65-26.5 ± 6.56-19.1 ± 6.78-29.5 ± 6.69-30.1 ± 6.77-28.4 ± 6.80-35.5 ± 6.55-34.8 ± 6.60
SecondaryChange From Baseline to Week 26 in VLDL / Chylomicron Triglycerides

The change from Baseline in VLDL/chylomicron triglyceride levels was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR VLDL/chylomicron triglycerides as continuous covariates.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · mg/dL
Change From Baseline to Week 26 in VLDL / Chylomicron Triglycerides
mg/dLPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 26 in VLDL / Chylomicron Triglycerides11.9 ± 7.238.3 ± 7.39-7.0 ± 7.29-20.4 ± 7.41-20.4 ± 7.29-23.8 ± 7.29-8.2 ± 7.41-23.5 ± 7.35-18.9 ± 7.41-10.4 ± 7.41-32.3 ± 7.26-26.2 ± 7.26
SecondaryChange From Baseline in VLDL Particles Over Time (Grouped Analysis)

The change from Baseline in levels of medium VLDL particles and small VLDL particles was assessed by NMR fractionation at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR VLDL particles as continuous covariates.

Time frame:
Baseline and Weeks 12 and 26
Reported as:
Least squares mean · nmol/L
Change From Baseline in VLDL Particles Over Time (Grouped Analysis)
nmol/LPioglitazone AloneAlogliptin 12.5 + PioglitazoneAlogliptin 25 + Pioglitazone
Medium Particles - Week 12 (n=332, 345, 343)-4.44 ± 1.174-5.36 ± 1.152-7.30 ± 1.155
Medium Particles - Week 26 (n=348, 359, 357)-2.28 ± 1.346-3.02 ± 1.326-4.88 ± 1.329
Small Particles - Week 12 (n=332, 345, 343)4.16 ± 1.0531.33 ± 1.0331.91 ± 1.035
Small Particles - Week 26 (n=348, 359, 357)2.30 ± 1.0843.55 ± 1.0675.22 ± 1.070
SecondaryChange From Baseline to Week 12 in VLDL Particles

The change from Baseline in levels of medium VLDL particles and small VLDL particles was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR VLDL particles as continuous covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · nmol/L
Change From Baseline to Week 12 in VLDL Particles
nmol/LPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Medium Particles2.13 ± 1.962-1.13 ± 2.014-2.88 ± 2.003-2.25 ± 2.011-3.16 ± 2.004-6.51 ± 1.977-2.59 ± 2.041-6.70 ± 2.013-7.05 ± 2.039-8.64 ± 2.048-6.38 ± 1.971-8.50 ± 1.987
Small Particles2.76 ± 1.7580.39 ± 1.804-2.30 ± 1.7975.99 ± 1.8031.16 ± 1.7962.60 ± 1.7724.39 ± 1.8291.15 ± 1.8062.51 ± 1.8282.22 ± 1.8391.80 ± 1.7650.73 ± 1.780
SecondaryChange From Baseline to Week 26 in VLDL Particles

The change from Baseline in levels of medium VLDL particles and small VLDL particles was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR VLDL particles as continuous covariates

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · nmol/L
Change From Baseline to Week 26 in VLDL Particles
nmol/LPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Medium Particles1.54 ± 2.2750.85 ± 2.324-2.94 ± 2.292-4.43 ± 2.331-1.78 ± 2.293-5.42 ± 2.2920.28 ± 2.332-2.17 ± 2.313-4.38 ± 2.331-2.70 ± 2.331-5.09 ± 2.285-4.83 ± 2.284
Small Particles0.26 ± 1.831-0.87 ± 1.868-2.91 ± 1.8462.83 ± 1.876-0.19 ± 1.8451.90 ± 1.8454.16 ± 1.8774.07 ± 1.8635.45 ± 1.876-0.08 ± 1.8786.77 ± 1.8378.33 ± 1.837
SecondaryChange From Baseline in Mean VLDL Particle Size Over Time (Grouped Analysis)

The change from Baseline in mean VLDL particle size was assessed by NMR lipid fractionation at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline mean VLDL particle size as continuous covariates.

Time frame:
Baseline and Weeks 12 and 26
Reported as:
Least squares mean · nm
Change From Baseline in Mean VLDL Particle Size Over Time (Grouped Analysis)
nmPioglitazone AloneAlogliptin 12.5 + PioglitazoneAlogliptin 25 + Pioglitazone
Week 12 (n=332, 344, 343)-2.77 ± 0.398-2.98 ± 0.390-3.02 ± 0.391
Week 26 (n=348, 358, 357)-2.49 ± 0.406-3.67 ± 0.400-3.26 ± 0.400
SecondaryChange From Baseline to Week 12 in Mean VLDL Particle Size

The change from Baseline in mean VLDL particle size was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline mean VLDL particle size as continuous covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · nm
Change From Baseline to Week 12 in Mean VLDL Particle Size
nmPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 12 in Mean VLDL Particle Size0.65 ± 0.6640.12 ± 0.681-0.18 ± 0.678-2.81 ± 0.681-2.10 ± 0.681-2.56 ± 0.669-3.16 ± 0.690-2.88 ± 0.681-2.49 ± 0.690-2.37 ± 0.694-4.00 ± 0.666-4.03 ± 0.672
SecondaryChange From Baseline to Week 26 in Mean VLDL Particle Size

The change from Baseline in mean VLDL particle size was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline mean VLDL particle size as continuous covariates.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · nm
Change From Baseline to Week 26 in Mean VLDL Particle Size
nmPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 26 in Mean VLDL Particle Size0.26 ± 0.6850.52 ± 0.7000.35 ± 0.691-2.99 ± 0.703-2.66 ± 0.694-2.36 ± 0.691-2.88 ± 0.703-3.69 ± 0.697-3.30 ± 0.702-1.60 ± 0.703-4.65 ± 0.688-4.12 ± 0.688
SecondaryChange From Baseline in Intermediate Density Lipoprotein (IDL) Particles Over Time (Grouped Analysis)

The change from Baseline in levels of IDL particles was assessed by NMR lipid fractionation at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR IDL particles as continuous covariates.

Time frame:
Baseline and Weeks 12 and 26
Reported as:
Least squares mean · nmol/L
Change From Baseline in Intermediate Density Lipoprotein (IDL) Particles Over Time (Grouped Analysis)
nmol/LPioglitazone AloneAlogliptin 12.5 + PioglitazoneAlogliptin 25 + Pioglitazone
Week 12 (n=332, 345, 343)0.4 ± 2.16-3.9 ± 2.12-5.7 ± 2.12
Week 26 (n=348, 359, 357)2.8 ± 2.16-4.2 ± 2.13-1.5 ± 2.13
SecondaryChange From Baseline to Week 12 in IDL Particles

The change from Baseline in levels of IDL particles was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR IDL particles as continuous covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · nmol/L
Change From Baseline to Week 12 in IDL Particles
nmol/LPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 12 in IDL Particles1.6 ± 3.60-11.1 ± 3.70-6.0 ± 3.685.1 ± 3.70-6.0 ± 3.68-2.3 ± 3.64-2.2 ± 3.75-6.3 ± 3.70-8.1 ± 3.75-1.5 ± 3.760.7 ± 3.62-6.5 ± 3.65
SecondaryChange From Baseline to Week 26 in IDL Particles

The change from Baseline in levels of IDL particles was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR IDL particles as continuous covariates.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · nmol/L
Change From Baseline to Week 26 in IDL Particles
nmol/LPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 26 in IDL Particles5.1 ± 3.65-7.3 ± 3.73-3.2 ± 3.685.2 ± 3.74-2.4 ± 3.670.0 ± 3.683.0 ± 3.74-5.0 ± 3.71-5.5 ± 3.740.1 ± 3.74-5.0 ± 3.661.0 ± 3.66
SecondaryChange From Baseline in Low Density Lipoprotein (LDL) Particles Over Time (Grouped Analysis)

The change from Baseline in levels of total, large, medium-small, total small and very small LDL particles was assessed by NMR fractionation at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR LDL particles as continuous covariates.

Time frame:
Baseline and Weeks 12 and 26
Reported as:
Least squares mean · nmol/L
Change From Baseline in Low Density Lipoprotein (LDL) Particles Over Time (Grouped Analysis)
nmol/LPioglitazone AloneAlogliptin 12.5 + PioglitazoneAlogliptin 25 + Pioglitazone
Total Particles - Week 12 (n=332, 345, 343)-104.1 ± 17.46-180.5 ± 17.13-236.8 ± 17.18
Total Particles - Week 26 (n=348, 359, 357)-78.2 ± 17.83-146.2 ± 17.55-182.9 ± 17.60
Large Particles - Week 12 (n=332, 345, 343)85.5 ± 10.02111.6 ± 9.83102.3 ± 9.85
Large Particles - Week 26 (n=348, 359, 357)95.8 ± 11.1193.9 ± 10.93106.1 ± 10.96
Medium-Small Particles - Week 12 (n=332, 345, 343)-36.6 ± 4.11-55.3 ± 4.03-60.1 ± 4.04
Medium-Small Particles - Week 26 (n=348, 359, 357)-34.3 ± 4.22-44.9 ± 4.16-49.6 ± 4.17
Total Small Particles - Week 12 (n=332, 345, 343)-191.4 ± 20.32-287.5 ± 19.94-331.4 ± 20.00
Total Small Particles - Week 26 (n=348, 359, 357)-178.1 ± 21.13-235.0 ± 20.81-285.9 ± 20.87
Very Small Particles - Week 12 (n=332, 345, 343)-154.6 ± 16.53-232.3 ± 16.23-271.3 ± 16.27
Very Small Particles - Week 26 (n=348, 359, 357)-143.6 ± 17.23-190.3 ± 16.97-236.2 ± 17.02
SecondaryChange From Baseline to Week 12 in LDL Particles

The change from Baseline in levels of total, large, medium-small, total small and very small LDL particles was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR LDL particles as continuous covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · nmol/L
Change From Baseline to Week 12 in LDL Particles
nmol/LPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Total Particles52.0 ± 29.17-39.1 ± 29.92-69.9 ± 29.80-48.8 ± 29.91-143.5 ± 29.79-175.6 ± 29.43-96.2 ± 30.37-195.8 ± 29.93-248.8 ± 30.31-167.0 ± 30.46-202.2 ± 29.27-285.8 ± 29.52
Large Particles4.7 ± 16.7421.1 ± 17.16-8.0 ± 17.0956.2 ± 17.1573.8 ± 17.0885.7 ± 16.8683.9 ± 17.43126.2 ± 17.18105.7 ± 17.39116.9 ± 17.48135.2 ± 16.79116.1 ± 16.95
Medium-Small Particles9.4 ± 6.87-7.7 ± 7.04-5.1 ± 7.02-20.3 ± 7.04-41.1 ± 7.01-48.0 ± 6.93-34.4 ± 7.14-58.2 ± 7.05-64.1 ± 7.14-55.4 ± 7.17-66.8 ± 6.89-68.2 ± 6.96
Total Small Particles45.1 ± 33.98-52.0 ± 34.83-56.5 ± 34.70-109.9 ± 34.83-211.0 ± 34.69-256.3 ± 34.26-184.1 ± 35.32-313.7 ± 34.85-345.4 ± 35.29-280.4 ± 35.46-337.9 ± 34.08-392.7 ± 34.38
Very Small Particles36.4 ± 27.65-44.1 ± 28.34-51.9 ± 28.23-89.2 ± 28.33-170.3 ± 28.22-207.6 ± 27.87-149.8 ± 28.74-255.7 ± 28.36-281.5 ± 28.72-225.0 ± 28.85-271.0 ± 27.73-325.0 ± 27.97
SecondaryChange From Baseline to Week 26 in LDL Particles

The change from Baseline in levels of total, large, medium-small, total small and very small LDL particles was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR LDL particles as continuous covariates.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · nmol/L
Change From Baseline to Week 26 in LDL Particles
nmol/LPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Total Particles15.0 ± 30.11-14.5 ± 30.73-30.8 ± 30.36-46.3 ± 30.86-115.1 ± 30.35-119.4 ± 30.37-68.6 ± 30.90-158.9 ± 30.62-209.4 ± 30.85-119.7 ± 30.87-164.6 ± 30.22-219.9 ± 30.21
Large Particles-23.8 ± 18.77-12.3 ± 19.1415.3 ± 18.9170.5 ± 19.2263.2 ± 18.9093.1 ± 18.9079.3 ± 19.2796.6 ± 19.09102.7 ± 19.22137.7 ± 19.23121.9 ± 18.83122.7 ± 18.83
Medium-Small Particles9.1 ± 7.140.0 ± 7.28-6.9 ± 7.20-25.8 ± 7.31-29.9 ± 7.19-36.2 ± 7.20-30.0 ± 7.32-47.4 ± 7.26-55.0 ± 7.31-47.1 ± 7.31-57.6 ± 7.16-57.8 ± 7.17
Total Small Particles32.4 ± 35.722.2 ± 36.44-42.9 ± 36.00-122.5 ± 36.59-175.1 ± 35.99-211.5 ± 36.01-154.9 ± 36.60-248.7 ± 36.31-304.9 ± 36.58-256.9 ± 36.58-281.1 ± 35.82-341.3 ± 35.82
Very Small Particles24.0 ± 29.132.5 ± 29.71-36.6 ± 29.36-96.3 ± 29.84-145.7 ± 29.35-174.5 ± 29.37-124.9 ± 29.85-201.6 ± 29.61-250.0 ± 29.83-209.6 ± 29.83-223.6 ± 29.22-283.9 ± 29.21
SecondaryChange From Baseline in Mean LDL Particle Size Over Time (Grouped Analysis)

The change from Baseline in mean LDL particle size was assessed by NMR lipid fractionation at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline mean LDL particle size as continuous covariates.

Time frame:
Baseline and Weeks 12 and 26
Reported as:
Least squares mean · nm
Change From Baseline in Mean LDL Particle Size Over Time (Grouped Analysis)
nmPioglitazone AloneAlogliptin 12.5 + PioglitazoneAlogliptin 25 + Pioglitazone
Week 12 (n=332, 345, 343)0.43 ± 0.0340.58 ± 0.0340.61 ± 0.034
Week 26 (n=348, 359, 357)0.41 ± 0.0360.47 ± 0.0350.54 ± 0.036
SecondaryChange From Baseline to Week 12 in Mean LDL Particle Size

The change from Baseline in mean LDL particle size was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline mean LDL particle size as continuous covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · nm
Change From Baseline to Week 12 in Mean LDL Particle Size
nmPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 12 in Mean LDL Particle Size-0.05 ± 0.0570.13 ± 0.0590.06 ± 0.0590.25 ± 0.0590.43 ± 0.0590.49 ± 0.0580.44 ± 0.0600.61 ± 0.0590.61 ± 0.0600.58 ± 0.0600.68 ± 0.0580.73 ± 0.058
SecondaryChange From Baseline to Week 26 in Mean LDL Particle Size

The change from Baseline in mean LDL particle size was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline mean LDL particle size as continuous covariates.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · nm
Change From Baseline to Week 26 in Mean LDL Particle Size
nmPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 26 in Mean LDL Particle Size-0.06 ± 0.061-0.01 ± 0.0620.07 ± 0.0610.26 ± 0.0620.38 ± 0.0610.41 ± 0.0610.38 ± 0.0620.48 ± 0.0620.57 ± 0.0620.59 ± 0.0620.55 ± 0.0610.63 ± 0.061
SecondaryChange From Baseline in High Density Lipoprotein (HDL) Particles Over Time (Grouped Analysis)

The change from Baseline in levels of total, large, medium and small HDL particles was assessed by NMR fractionation at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR HDL particles as continuous covariates.

Time frame:
Baseline and Weeks 12 and 26.
Reported as:
Least squares mean · μMOL/L
Change From Baseline in High Density Lipoprotein (HDL) Particles Over Time (Grouped Analysis)
μMOL/LPioglitazone AloneAlogliptin 12.5 + PioglitazoneAlogliptin 25 + Pioglitazone
Total Particles - Week 12 (n=332, 345, 343)0.86 ± 0.2200.58 ± 0.2160.43 ± 0.216
Total Particles - Week 26 (n=348, 359, 357)0.62 ± 0.2351.18 ± 0.2310.78 ± 0.232
Large Particles - Week 12 (n=332, 345, 343)0.89 ± 0.1110.78 ± 0.1090.89 ± 0.109
Large Particles - Week 26 (n=348, 359, 357)0.81 ± 0.1230.90 ± 0.1211.01 ± 0.122
Medium Particles - Week 12 (n=332, 345, 343)1.38 ± 0.1951.16 ± 0.1911.63 ± 0.191
Medium Particles - Week 26 (n=348, 359, 357)1.34 ± 0.1951.10 ± 0.1921.46 ± 0.192
Small Particles - Week 12 (n=332, 345, 343)-1.35 ± 0.261-1.39 ± 0.256-2.12 ± 0.256
Small Particles - Week 26 (n=348, 359, 357)-1.45 ± 0.261-0.85 ± 0.257-1.73 ± 0.258
SecondaryChange From Baseline to Week 12 in HDL Particles

The change from Baseline in levels of total, large, medium and small HDL particles was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR HDL particles as continuous covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · μmol/L
Change From Baseline to Week 12 in HDL Particles
μmol/LPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Total Particles-0.08 ± 0.368-0.06 ± 0.3770.16 ± 0.3750.90 ± 0.3770.37 ± 0.3750.55 ± 0.3701.29 ± 0.3820.75 ± 0.3770.15 ± 0.3820.40 ± 0.3840.63 ± 0.3690.60 ± 0.372
Large Particles-0.21 ± 0.185-0.29 ± 0.190-0.10 ± 0.1890.53 ± 0.1900.24 ± 0.1890.50 ± 0.1861.09 ± 0.1920.95 ± 0.1901.12 ± 0.1921.06 ± 0.1931.17 ± 0.1861.06 ± 0.187
Medium Particles0.17 ± 0.325-0.24 ± 0.333-0.01 ± 0.3320.81 ± 0.3341.15 ± 0.3320.65 ± 0.3281.21 ± 0.3380.97 ± 0.3341.89 ± 0.3382.06 ± 0.3391.30 ± 0.3262.31 ± 0.329
Small Particles-0.07 ± 0.4350.43 ± 0.4470.27 ± 0.445-0.25 ± 0.446-1.09 ± 0.445-0.63 ± 0.439-0.92 ± 0.453-1.18 ± 0.447-2.82 ± 0.452-2.82 ± 0.455-1.84 ± 0.437-2.84 ± 0.441
SecondaryChange From Baseline to Week 26 in HDL Particles

The change from Baseline in levels of total, large, medium and small HDL particles was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR HDL particles as continuous covariates.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · μmol/L
Change From Baseline to Week 26 in HDL Particles
μmol/LPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Total Particles0.18 ± 0.3970.43 ± 0.4051.03 ± 0.4000.37 ± 0.4070.77 ± 0.4001.31 ± 0.4000.67 ± 0.4071.15 ± 0.4030.26 ± 0.4060.83 ± 0.4071.61 ± 0.3980.77 ± 0.398
Large Particles0.02 ± 0.208-0.16 ± 0.2120.39 ± 0.2100.53 ± 0.2130.55 ± 0.2100.75 ± 0.2100.64 ± 0.2131.13 ± 0.2121.34 ± 0.2131.26 ± 0.2131.02 ± 0.2090.95 ± 0.209
Medium Particles0.13 ± 0.3300.16 ± 0.3360.54 ± 0.3320.81 ± 0.3380.86 ± 0.3320.67 ± 0.3321.48 ± 0.3381.47 ± 0.3351.69 ± 0.3371.71 ± 0.3370.96 ± 0.3312.01 ± 0.330
Small Particles0.00 ± 0.4410.41 ± 0.4500.10 ± 0.444-0.78 ± 0.452-0.68 ± 0.444-0.17 ± 0.444-1.35 ± 0.452-1.47 ± 0.448-2.77 ± 0.452-2.21 ± 0.452-0.40 ± 0.443-2.24 ± 0.442
SecondaryChange From Baseline in Mean HDL Particle Size Over Time (Grouped Analysis)

The change from Baseline in mean HDL particle size was assessed by NMR lipid fractionation at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline mean HDL particle size as continuous covariates.

Time frame:
Baseline and Weeks 12 and 26
Reported as:
Least squares mean · nm
Change From Baseline in Mean HDL Particle Size Over Time (Grouped Analysis)
nmPioglitazone AloneAlogliptin 12.5 + PioglitazoneAlogliptin 25 + Pioglitazone
Week 12 (n=332, 345, 343)0.11 ± 0.0130.13 ± 0.0130.16 ± 0.013
Week 26 (n=348, 359, 357)0.11 ± 0.0150.12 ± 0.0140.17 ± 0.014
SecondaryChange From Baseline to Week 12 in Mean HDL Particle Size

The change from Baseline in mean HDL particle size was assessed by NMR lipid fractionation. Least squares means are from are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline mean HDL particle size as continuous covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · nm
Change From Baseline to Week 12 in Mean HDL Particle Size
nmPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 12 in Mean HDL Particle Size0.00 ± 0.0230.00 ± 0.0230.00 ± 0.0230.06 ± 0.0230.07 ± 0.0230.09 ± 0.0230.10 ± 0.0230.15 ± 0.0230.17 ± 0.0230.18 ± 0.0240.17 ± 0.0230.21 ± 0.023
SecondaryChange From Baseline to Week 26 in Mean HDL Particle Size

The change from Baseline in mean HDL particle size was assessed by NMR lipid fractionation. Least squares means are from are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline mean HDL particle size as continuous covariates.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · nm
Change From Baseline to Week 26 in Mean HDL Particle Size
nmPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
Change From Baseline to Week 26 in Mean HDL Particle Size0.03 ± 0.0250.00 ± 0.0250.07 ± 0.0250.06 ± 0.0250.06 ± 0.0250.11 ± 0.0250.10 ± 0.0250.15 ± 0.0250.20 ± 0.0250.19 ± 0.0250.16 ± 0.0250.19 ± 0.025

Adverse events

Collected over Adverse events were collected from the time of informed consent until the end of the study, and from spontaneous reporting for 30 days after the end of treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—2/129 (1.6%)41/129 (31.8%)
Alogliptin 12.5 + Placebo—5/128 (3.9%)40/128 (31.3%)
Alogliptin 25 + Placebo—6/129 (4.7%)46/129 (35.7%)
Placebo + Pioglitazone 15—1/129 (0.8%)51/129 (39.5%)
Alogliptin 12.5 + Pioglitazone 15—2/130 (1.5%)45/130 (34.6%)
Alogliptin 25 + Pioglitazone 15—1/130 (0.8%)44/130 (33.8%)
Placebo + Pioglitazone 30—2/129 (1.6%)40/129 (31%)
Alogliptin 12.5 + Pioglitazone 30—3/130 (2.3%)35/130 (26.9%)
Alogliptin 25 + Pioglitazone 30—6/130 (4.6%)51/130 (39.2%)
Placebo + Pioglitazone 45—10/129 (7.8%)40/129 (31%)
Alogliptin 12.5 + Pioglitazone 45—2/130 (1.5%)47/130 (36.2%)
Alogliptin 25 + Pioglitazone 45—5/130 (3.8%)41/130 (31.5%)
Most frequent serious events
Showing 10 of 48
Most frequent serious events
EventPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
PancreatitisGastrointestinal disorders0/1291/1280/1290/1290/1300/1300/1290/1300/1300/1290/1300/130
PeriodontitisGastrointestinal disorders0/1291/1280/1290/1290/1300/1300/1290/1300/1300/1290/1300/130
CholelithiasisHepatobiliary disorders0/1291/1280/1290/1290/1300/1300/1290/1300/1300/1290/1300/130
Urinary tract infectionInfections and infestations0/1291/1280/1290/1290/1300/1300/1290/1300/1300/1290/1300/130
Nerve compressionNervous system disorders0/1291/1280/1290/1290/1300/1300/1290/1300/1300/1290/1300/130
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/1291/1280/1290/1290/1300/1300/1290/1300/1300/1290/1300/130
Coronary artery diseaseCardiac disorders0/1290/1280/1290/1290/1300/1300/1290/1300/1301/1290/1300/130
Myocardial infarctionCardiac disorders0/1290/1280/1290/1290/1300/1300/1290/1300/1301/1290/1300/130
Umbilical herniaGastrointestinal disorders0/1290/1280/1290/1290/1300/1300/1290/1300/1301/1290/1300/130
Non-cardiac chest painGeneral disorders0/1290/1281/1290/1290/1300/1301/1290/1300/1300/1290/1300/130
Most frequent other events
Showing 10 of 14
Most frequent other events
EventPlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45
HeadacheNervous system disorders6/1295/1289/12916/1295/1303/1302/1292/1305/1305/1296/1306/130
Back painMusculoskeletal and connective tissue disorders5/1291/1287/1295/1296/1305/1303/1292/1308/1304/12912/1303/130
DiarrhoeaGastrointestinal disorders11/1292/1284/1295/1293/1306/1304/1292/1307/1305/1294/1307/130
InfluenzaInfections and infestations3/1294/1284/1299/1294/1308/1307/1292/1308/1305/1293/1302/130
NasopharyngitisInfections and infestations5/1295/1284/1293/1298/1308/1304/1295/1309/1304/1296/1304/130
HypertensionVascular disorders4/1296/1284/1296/1299/1303/1302/1293/1303/1302/1295/1301/130
Urinary tract infectionInfections and infestations6/1296/1285/1297/1295/1306/1308/1294/1304/1308/1295/1305/130
Upper respiratory tract infectionInfections and infestations5/1293/1288/1293/1292/1304/1301/1295/1304/1302/1294/1304/130
HypertriglyceridaemiaMetabolism and nutrition disorders3/1297/1286/1295/1292/1303/1305/1292/1304/1303/1293/1301/130
DyslipidaemiaMetabolism and nutrition disorders0/1291/1281/1293/1293/1301/1302/1291/1304/1307/1291/1302/130

Baseline characteristics

Age Continuous
Age Continuous(years)PlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45Total
Mean55.2 ± 9.8953.1 ± 9.5953.7 ± 9.3154.1 ± 9.5453.6 ± 9.9154.9 ± 9.1856.1 ± 9.4355.0 ± 9.0754.4 ± 9.6954.5 ± 9.7054.0 ± 9.8254.2 ± 8.8654.4 ± 9.50
Age, Customized
Age, Customized(participants)PlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45Total
<65 years1061161121131091121011111071121111121322
≥65 years231217172118281923171918232
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45Total
Female686179697069667675767078857
Male616750616061635455536052697
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45Total
Hispanic or Latino636063635557676662616365745
Not Hispanic or Latino666866677573626468686765809
Unknown or Not Reported0000000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45Total
American Indian or Alaska Native0000220100005
Asian5141511971051212812120
Native Hawaiian or Other Pacific Islander0000000000000
Black or African American86584362599368
White93898085959696107858592931096
More than one race0000000000000
Unknown or Not Reported231929262022171528232122265
Weight
Weight(kg)PlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45Total
Mean83.38 ± 18.37884.63 ± 19.37883.25 ± 18.32684.68 ± 18.63485.95 ± 18.49882.90 ± 16.57085.86 ± 20.34783.68 ± 18.34085.77 ± 18.84482.10 ± 17.01985.01 ± 18.53682.79 ± 18.76884.17 ± 18.470
Height
Height(cm)PlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45Total
Mean164.48 ± 10.157164.61 ± 10.614162.38 ± 9.790164.25 ± 11.007164.59 ± 10.841163.74 ± 10.456164.59 ± 9.724163.63 ± 11.036163.64 ± 9.548163.14 ± 10.961163.82 ± 10.708163.73 ± 11.432163.88 ± 10.522
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)PlaceboAlogliptin 12.5 + PlaceboAlogliptin 25 + PlaceboPlacebo + Pioglitazone 15Alogliptin 12.5 + Pioglitazone 15Alogliptin 25 + Pioglitazone 15Placebo + Pioglitazone 30Alogliptin 12.5 + Pioglitazone 30Alogliptin 25 + Pioglitazone 30Placebo + Pioglitazone 45Alogliptin 12.5 + Pioglitazone 45Alogliptin 25 + Pioglitazone 45Total
Mean30.59 ± 4.80830.96 ± 5.13331.48 ± 5.73331.25 ± 5.28031.53 ± 4.97930.78 ± 4.72331.41 ± 5.39131.09 ± 5.05431.86 ± 5.58530.69 ± 4.72131.51 ± 5.20630.62 ± 4.75131.15 ± 5.122

2 further baseline measures are reported on the registry.

08

Study locations

90 sites
  • Birmingham, Alabama, United States
  • Columbiana, Alabama, United States
  • Huntsville, Alabama, United States
  • Phoenix, Arizona, United States
  • Little Rock, Arkansas, United States
  • Searcy, Arkansas, United States
  • Sherwood, Arkansas, United States
  • Burbank, California, United States
  • Foothill Ranch, California, United States
  • Irvine, California, United States
  • Sacramento, California, United States
  • San Diego, California, United States
  • Temecula, California, United States
  • Tustin, California, United States
  • Colorado Springs, Colorado, United States
  • Washington, District of Columbia, United States
  • Hollywood, Florida, United States
  • Kissimmee, Florida, United States
  • Miami, Florida, United States
  • New Port Richey, Florida, United States
  • Pembroke Pines, Florida, United States
  • Pinellas Park, Florida, United States
  • Sarasota, Florida, United States
  • Vero Beach, Florida, United States
  • Atlanta, Georgia, United States
  • Roswell, Georgia, United States
  • Savannah, Georgia, United States
  • Warner Robins, Georgia, United States
  • Chicago, Illinois, United States
  • Peoria, Illinois, United States
  • Lafayette, Indiana, United States
  • South Bend, Indiana, United States
  • Waterloo, Iowa, United States
  • Munfordville, Kentucky, United States
  • Baton Rouge, Louisiana, United States
  • Marrero, Louisiana, United States
  • Elkridge, Maryland, United States
  • Prince Frederick, Maryland, United States
  • Towson, Maryland, United States
  • Marlborough, Massachusetts, United States
  • Ann Arbor, Michigan, United States
  • Cadillac, Michigan, United States
  • Detroit, Michigan, United States
  • Livonia, Michigan, United States
  • Kansas City, Missouri, United States
  • North Las Vegas, Nevada, United States
  • Blackwood, New Jersey, United States
  • Trenton, New Jersey, United States
  • New York, New York, United States
  • Charlotte, North Carolina, United States
  • Statesville, North Carolina, United States
  • Gallipolis, Ohio, United States
  • Marion, Ohio, United States
  • Clinton, Oklahoma, United States
  • Oklahoma City, Oklahoma, United States
  • Tulsa, Oklahoma, United States
  • Allentown, Pennsylvania, United States
  • Altoona, Pennsylvania, United States
  • Philadelphia, Pennsylvania, United States
  • Pittsburgh, Pennsylvania, United States
  • Alcoa, Tennessee, United States
  • Milan, Tennessee, United States
  • Morristown, Tennessee, United States
  • Arlington, Texas, United States
  • Carrollton, Texas, United States
  • Dallas, Texas, United States
  • Fort Worth, Texas, United States
  • Houston, Texas, United States
  • San Antonio, Texas, United States
  • Temple, Texas, United States
  • Salt Lake City, Utah, United States
  • Burlington, Vermont, United States
  • Multiple Cities, Australia
  • Multiple Cities, Brazil
  • Multiple Cities, Bulgaria
  • Multiple Cities, Chile
  • Multiple Cities, Croatia
  • Multiple Cities, Estonia
  • Multiple Cities, Guatemala
  • Multiple Cities, India
  • Multiple Cities, Israel
  • Multiple Cities, Latvia
  • Multiple Cities, Mexico
  • Multiple Cities, New Zealand
  • Multiple Cities, Peru
  • Multiple Cities, Romania
  • Multiple Cities, Russian Federation
  • Multiple Cities, Serbia
  • Multiple Cities, South Africa
  • Multiple Cities, Ukraine
09

References and documents

Publications

  • DeFronzo RA, Burant CF, Fleck P, Wilson C, Mekki Q, Pratley RE. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes. J Clin Endocrinol Metab. 2012 May;97(5):1615-22. doi: 10.1210/jc.2011-2243. Epub 2012 Mar 14. PubMed 22419732 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006, a primary completion of Mar 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2013, 5 years 1 month after primary completion. A results delay was requested in Jul 2009.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2006
First posted
May 22, 2006
Start
May 2006
Primary completionActual
Mar 2008
CompletionActual
Mar 2008
Results delay requested
Jul 30, 2009
Results first posted
Apr 4, 2013
Last update
Apr 4, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00328627
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
May 22, 2006
Start date
May 2006
Primary completion
Mar 2008
Completion
Mar 2008
Results posted
Apr 4, 2013
Last update
Apr 4, 2013

Study contacts

VP Biological Sciences
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Alogliptin · Pioglitazone

Start the discussion